Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. The first indication the Company plans to pursue is development of SAN711 for essential tremor, a neurological condition that includes shaking or trembling movements in one or more parts of the bo.
- 11/26/2024
|
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: Citi's 2024 Global Healthcare Conference Fireside Chat: Tuesday, December 3, 2024 at 10:15 a.m. Eastern Time in Miami, FL 7th Annual Evercore HealthCONx Conference Fireside Chat: Wednesday, December 4, 2024 at 2:35 p.m. Eastern Time in Coral Gables, FL Live webcasts of each fireside chat will be accessible on the company's website, Acadia.com, und.
- 11/21/2024
|
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on November 8, 2024, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 70,571 shares of common stock and 40,731 restricted stock units (“RSUs”) to twenty-three new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employ.
- 11/15/2024
|
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 11/12/2024
|
Acadia Pharmaceuticals: Proving The Naysayers Wrong
- Today, we are revisiting with mid-cap biopharma Acadia Pharmaceuticals Inc., whose stock surged some 20% last week following Q3 results. The company beat both top and bottom-line expectations and also posted updated FY2024 guidance. Acadia Pharmaceuticals is becoming profitable, has a pristine balance sheet, and is seeing solid growth.
- 11/11/2024
|
Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth
- ACAD reports encouraging third-quarter results as earnings and revenues beat estimates. Nuplazid and Daybue sales record year-over-year growth.
- 11/07/2024
|
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript
- ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript
- 11/06/2024
|
Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates
- Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to loss of $0.40 per share a year ago.
- 11/06/2024
|
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction. Acadia was granted the PRV in March 2023 following approval by the U.S. Food and Drug Administration (FDA) of DAYBUE™ (trofinetide) for the treatment of Rett syndrome. DAYBUE was initially licensed by Acadia from Neuren Pharmaceutical.
- 11/05/2024
|
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/30/2024
|
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on November 6, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call will be available on Acadia's website, Acadia.com under the investors section and will be archived.
- 10/17/2024
|
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has granted marketing authorization of DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older under the Priority Review process. The Notice of Compliance authorization of DAYBUE makes it the first and only drug approved in Canada for the treatment of Rett syndrome. Rett syndrome is a rare, complex, neurodevelopmental disorder affe.
- 10/16/2024
|
Why Acadia (ACAD) Could Beat Earnings Estimates Again
- Acadia (ACAD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/14/2024
|
ACAD or TECH: Which Is the Better Value Stock Right Now?
- Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Acadia Pharmaceuticals (ACAD) and Techne (TECH). But which of these two stocks is more attractive to value investors?
- 10/09/2024
|
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on October 3, 2024, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 111,631 shares of common stock and 30,484 restricted stock units (“RSUs”) to thirteen new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees'.
- 10/08/2024
|
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on September 23, 2024, the Board of Directors granted Catherine Owen Adams, Acadia's new Chief Executive Officer, a one-time sign-on equity award of (i) 353,261 options to purchase shares of Acadia's common stock with an exercise price of $16.29 per share, Acadia's closing trading price on September 23, 2024, which vest 25% on the first anniversary of grant and in equal monthly installments over the thre.
- 09/26/2024
|
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive Officer (CEO) and joined the Acadia Board of Directors. “We are excited to welcome Catherine Owen Adams as the new CEO of Acadia,” said Stephen Biggar, M.D., Ph.D., Chair of the Board of Directors. “Catherine is a proven global leader with a distinguished record of accomplishment of driving growth and innovation in the pharmaceutical indus.
- 09/23/2024
|
Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals
- TOKYO--(BUSINESS WIRE)-- #DrugDiscovery--Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals.
- 09/19/2024
|
Acadia (ACAD) Up 10% Since Last Earnings Report: Can It Continue?
- Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
- 09/05/2024
|
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference Fireside Chat: Wednesday, September 4, 2024 at 4:50 p.m. Eastern Time in New York, NY Baird 2024 Global Healthcare Conference Fireside Chat: Wednesday, September 11, 2024 at 9:40 a.m. Eastern Time in New York, NY Live webcasts of each fireside chat will be accessible on the company's website,.
- 08/28/2024
|
Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
- Shares of Acadia trended lower this year due to Daybue's poor quarterly sales performance, and also due to Nuplazid's failure in the phase 3 trial in schizophrenia patients. The full-year guidance on Daybue was reduced as Acadia is finding fewer new patients, not because of higher patient churn. With most of the headwinds in the rearview mirror, I expect better performance of Daybue going forward.
- 08/26/2024
|
Ryan Reynolds Announces More to Parkinson's® Campaign
- SAN DIEGO--(BUSINESS WIRE)--Ryan Reynolds, a world-renowned actor/entrepreneur and Parkinson's disease advocate, with Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of a multi-faceted disease education campaign, More to Parkinson's®, to raise awareness among caregivers, patients and their care providers about a common, yet under-recognized aspect of Parkinson's disease – Parkinson's-related hallucinations and delusions. Notably, around half of the people living with Parki.
- 08/14/2024
|
Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues
- Acadia (ACAD) reports encouraging second-quarter results as both earnings and revenues beat estimates, driven by higher Nuplazid and Daybue sales.
- 08/07/2024
|
ACADIA Pharmaceuticals Inc. (ACAD) Q2 2024 Earnings Call Transcript
- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Al Kildani - Senior Vice President, Investor Relations and Corporate Communications Steve Davis - President and Chief Executive Officer Brendan Teehan - Chief Operating Officer, Head of Commercial Kimberly Manhard - Senior Vice President, Global Strategic Planning and Execution Mark Schneyer - Chief Financial Officer Parag Meswani - Senior Vice President, Trofinetide Elizabeth Thompson - Executive Vice President, Head of Research and Development Conference Call Participants Ritu Baral - TD Cowen Charles Duncan - Cantor Anish Nikhanj - RBC Capital Markets Joel Beatty - Baird Marc Goodman - Leerink Jeff Hung - Morgan Stanley Keith Tapper - BMO Capital Markets David Hoang - Citigroup Eddie Hickman - Guggenheim Tessa Romero - JPMorgan Operator Good day ladies and gentlemen, and thank you for standing by. Welcome to the ACADIA Pharmaceuticals Second Quarter 2024 Financial Results Conference Call.
- 08/06/2024
|
Acadia Pharmaceuticals (ACAD) Beats Q2 Earnings and Revenue Estimates
- Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.01 per share a year ago.
- 08/06/2024
|
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/30/2024
|
HLN vs. LMAT: Which Stock Should Value Investors Buy Now?
- Acadia Pharmaceuticals ACAD is a commercial-stage company focused on developing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders and rare diseases. ACAD's commercial portfolio comprises two marketed drugs — Nuplazid (pimavanserin) and Daybue (trofinetide).
- 07/16/2024
|
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
- Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.
- 07/16/2024
|
Acadia Pharmaceuticals: Back In The Buy Zone
- Acadia Pharmaceuticals, Inc. shares recently hit their lowest level since Daybue approval due to Nuplazid Phase 3 trial failure for schizophrenia. Despite setbacks, Acadia has strong financials with $470.5 million in cash and investments, and is trading at two times FY24 revenue net of cash. An updated analysis around Acadia Pharmaceuticals follows in the paragraphs below.
- 06/23/2024
|
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be presented at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting, being held this week in Westminster, Colorado. LOTUS is an ongoing, caregiver-reported study evaluating the efficacy and tolerability outcomes in patients with Rett syndrome treated with DAYBUE™ (trofinetide). “These interim data from the LOTUS s.
- 06/18/2024
|
New Millie Report Finds Hybrid Maternal Healthcare Model Improve Deliveries, Patient Engagement and Cost Savings
- BERKELEY, Calif.--(BUSINESS WIRE)--Millie, a modern maternity clinic, today revealed promising maternal health outcomes from the first cohort of more than 150 births from its hybrid model that combines midwifery-led care, doulas, and OB-GYN support with technology to provide more complete, proactive, and right-sized care. Millie's 360-degree approach has shown the potential to improve key outcomes while also demonstrating a model for addressing national OB-GYN shortages. Health Outcomes In comp.
- 06/18/2024
|
Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue?
- Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
- 06/07/2024
|
Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS Treatments
- ACADIA Pharmaceuticals is a biopharmaceutical company specializing in CNS disorder treatments, with two successful FDA-approved commercial products, Nuplazid and Daybue. Nuplazid, indicated for Parkinson's disease psychosis, generates over $300 million in yearly cash flow, while Daybue, approved for Rett syndrome, had a successful launch. ACAD has a promising pipeline of drug candidates, including ACP-101 for Prader-Willi syndrome and ACP-204 for Alzheimer's disease psychosis, which could create additional revenue verticals.
- 06/05/2024
|
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on May 15, 2024, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 57,252 shares of common stock and 33,675 restricted stock units (“RSUs”) to twenty-two new employees under Acadia's 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' e.
- 05/17/2024
|
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of Magnolia's Guide to Adventuring, a new, 10-part, documentary video series by award-winning TV producer, AJ Tesler, and his wife, Jenny Tesler, featuring their 13-year-old daughter, Magnolia, who lives with Rett syndrome. The series follows the Teslers as they are joined by other Rett families on adaptive adventures across the U.S., including downhill skiing, ice skating and horseback riding, to.
- 05/15/2024
|
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: Citizens JMP Life Sciences Conference Fireside Chat: Tuesday, May 14, 2024 at 1:30 p.m. Eastern Time in New York, NY 2024 RBC Capital Markets Global Healthcare Conference Fireside Chat: Wednesday, May 15, 2024 at 11:30 a.m. Eastern Time in New York, NY BofA Securities Health Care Conference Fireside Chat: Wednesday, May 16, 2024 at 12:20 p.m. Ea.
- 05/09/2024
|
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
- Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.
- 05/09/2024
|
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript
- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Corporate Participants Al Kildani - Senior Vice President, Investor Relations and Corporate Communications Steve Davis - President and Chief Executive Officer Brendan Teehan - Chief Operating Officer, Head of Commercial Kimberly Manhard - Senior Vice President, Global Strategic Planning and Execution Mark Schneyer - Chief Financial Officer Conference Call Participants Tessa Romero - JPMorgan Ritu Baral - TD Cowen Gregory Renza - RBC Capital Markets Ami Fadia - Needham & Company Yatin Suneja - Guggenheim David Hoang - Citigroup Joel Beatty - Baird Elaine Kim - Cantor Jose Lora - Citizens JMP Ash Verma - UBS Marc Goodman - Leerink Sumanth Kulkarni - Canaccord Genuity Uy Ear - Mizuho Operator Good day, everyone, and thank you for standing by. Welcome to the ACADIA Pharmaceuticals First Quarter 2024 Financial Results and Operating Overview Conference Call.
- 05/08/2024
|
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates
- Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to loss of $0.27 per share a year ago.
- 05/08/2024
|
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
- Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
- 05/06/2024
|
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?
- Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/01/2024
|
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has awarded 10 academic scholarships to eligible recipients of the first Rett Sibling Scholarship. The Rett Sibling Scholarship program, sponsored by Acadia, was established in 2023 to recognize the siblings of individuals with Rett syndrome. This year's recipients will each receive $5,000 to pursue their goals in higher education for the 2024-25 academic school year. “Families affected by Rett syndro.
- 04/29/2024
|
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 8, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call will be available on Acadia's website, Acadia.com under the investors section and will be archived there unti.
- 04/24/2024
|
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted Priority Review for Acadia's submission. “Rett syndrome is a profoundly debilitating and complex neurodevelopmental disorder that presents differently across patients and can lead to an array of unpredictable symptoms,” said Pamela di C.
- 04/22/2024
|
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common stock and 12,739 restricted stock units (“RSUs”) to six new employees under Acadia's 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employ.
- 04/19/2024
|
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that two oral presentations featuring DAYBUE™ (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (AAN) 2024 annual meeting, being held this week in Denver, CO. The presentations include outcomes from the DAFFODIL™, a Phase 2/3 open-label study evaluating the safety, tolerability and exploratory efficacy of DAYBUE in girls aged two to four living with Rett syndrome,.
- 04/17/2024
|
3 Pharma Stocks to Sell in April Before They Crash & Burn
- There are some pharma stocks to sell in April. Holding these companies is too risky, especially as the industry faces increasing regulatory scrutiny and pricing pressures.
- 04/11/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/05/2024
|
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D.
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson will lead research and development at Acadia and serve as a member of the company's Executive Leadership Team, reporting to Steve Davis, Chief Executive Officer of Acadia. “Liz is a preeminent drug research and development leader with extensive experience in the advancement and commercia.
- 04/02/2024
|
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/01/2024
|
Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report?
- Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
- 03/28/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 03/28/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 03/26/2024
|
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 03/25/2024
|
Acadia Pharmaceuticals Stock Sinks After Schizophrenia Drug Study Falls Short
- Shares of Acadia Pharmaceuticals (ACAD) plunged more than 16% Tuesday after one of its current drugs failed to meet its goal for expanded use in a Phase 3 trial.
- 03/12/2024
|
Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails
- Acadia (ACAD) tumbles after its late-stage study on pimavanserin to treat negative symptoms of schizophrenia fails to achieve the primary goal with statistical significance.
- 03/12/2024
|
Why Are Airline Stocks Down Today?
- Airline stocks are down today as investors deal with several bits of bad news for the industry on Tuesday! Starting off the negative news today is Delta Air Lines (NYSE:DAL) with its latest quarterly outlook.
- 03/12/2024
|
Why Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today?
- Acadia Pharmaceuticals (NASDAQ: ACAD ) stock is falling on Tuesday after the company released results from a Phase 3 clinical trial of pimavanserin. Pimavanserin is a drug in development at Acadia Pharmaceuticals as a treatment for negative symptoms of schizophrenia.
- 03/12/2024
|
Acadia Pharma's stock falls 15% after failed drug trial
- Shares of Acadia Pharmaceuticals Inc. dropped more than 15% in the extended session Monday after one of the pharma company's drugs failed to meet goals of a late-stage trial about a schizophrenia treatment.
- 03/11/2024
|
Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down
- Acadia's (ACAD) fourth-quarter earnings miss estimates while revenues beat the same. Higher product sales drive year-over-year revenues.
- 02/28/2024
|
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates
- Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.28 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to loss of $0.26 per share a year ago.
- 02/27/2024
|
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?
- Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/20/2024
|
Culper Research takes short position in Acadia Pharma
- Culper Research said on Thursday it has taken a short position on Acadia Pharmaceuticals' stock.
- 02/15/2024
|
Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
- ACADIA Pharmaceuticals and Soleno Therapeutics are both conducting late-stage trials for the treatment of Prader-Willi Syndrome. PWS is a rare disease characterized by various physical and developmental challenges. Acadia is an established commercial stage company, while Soleno is a clinical stage company focused on PWS.
- 01/22/2024
|
HRMY or ACAD: Which Is the Better Value Stock Right Now?
- Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Acadia Pharmaceuticals (ACAD). But which of these two companies is the best option for those looking for undervalued stocks?
- 01/04/2024
|
Acadia's (ACAD) Nuplazid Sales Drive Growth Amid Competition
- Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, dependence on Nuplazid sales for revenues, along with stiff competition, remains a woe.
- 12/29/2023
|
Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 9:00 a.m. Pacific Time, followed by a question and answer session. A live webcast of Acadia's presentation will be accessible on the company's website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentat.
- 12/21/2023
|
Acadia Pharmaceuticals: Legal Overhang On Nuplazid Removed
- Shares of Acadia Pharmaceuticals surged after the Court granted a summary judgment in the Nuplazid patent case in its favor. The positive outcome removes an important legal overhang on ACAD stock and further share price advancements can be driven by Daybue's commercial success. Daybue continued to exceed expectations with a Q3 net sales beat and a strong Q4 outlook.
- 12/13/2023
|
Acadia's Daybue: A Small Patient Pool Making Big Waves
- Acadia's Daybue, treating Rett syndrome, shows strong market entry with sales of $90.1 million in the first six months, indicating significant market potential. Acadia's financials are robust with rising net product sales and a strong current ratio, but increasing operating expenses and net losses. Market confidence in Acadia is moderate, with high institutional ownership and insider buying, but mixed stock momentum.
- 12/10/2023
|
Acadia (ACAD) Begins Study on ACP-101 for Hyperphagia in PWS
- Acadia (ACAD) begins late-stage development of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome.
- 12/01/2023
|
Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study (Revised)
- Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.
- 11/30/2023
|
Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study
- Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.
- 11/28/2023
|
5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright
- New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.
- 11/22/2023
|
Are Medical Stocks Lagging ACADIA Pharmaceuticals (ACAD) This Year?
- Here is how Acadia Pharmaceuticals (ACAD) and Medpace (MEDP) have performed compared to their sector so far this year.
- 11/17/2023
|
3 Biotech Stocks With the Strongest Clinical Pipelines
- Biotech is still one of the most exciting sectors on the market. Recession-proof, the sector is still thriving with millions of retiring baby boomers, mergers and acquisitions, new innovation, the introduction of artificial intelligence with drug discovery and demand for new treatments.
- 11/08/2023
|
Acadia (ACAD) Q3 Earnings and Sales Beat Estimates, Stock Up
- Acadia (ACAD) reports better-than-expected third-quarter 2023 results as both earnings and sales beat estimates. The stock rises in after-market hours.
- 11/03/2023
|
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2023 Earnings Call Transcript
- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Jessica Tieszen - Associate Director of Investor Relations Albert Kildani - Senior Vice President, Investor Relations & Corporate Communications Steve Davis - Chief Executive Officer Brendan Teehan - Chief Operating Officer, Head of Commercial Doug Williamson - Head of Research & Development Mark Schneyer - Chief Financial Officer Parag Meswani - Senior Vice President: Trofinetide, Rare Diseases Franchise Kathie Bishop - Head of Rare Diseases & External Innovation Conference Call Participants Ritu Baral - TD Cowen Tessa Romero - J.P. Morgan Yatin Suneja - Guggenheim Charles Duncan - Cantor Fitzgerald Tazeen Ahmad - Bank of America Sumant Kulkarni - Canaccord Genuity Ami Fadia - Needham & Company Jay Olson - Oppenheimer Operator Good day ladies and gentlemen and welcome to ACADIA Pharmaceuticals Third Quarter 2023 Financial Results Conference Call.
- 11/03/2023
|
Reasons to Add Acadia (ACAD) Stock to Your Portfolio Now
- Here we discuss some reasons why investing in Acadia (ACAD) stock now may turn out to be a more prudent move than ever.
- 10/12/2023
|
Why Acadia Pharmaceuticals Stock Is Rising Today
- An analyst upgraded Acadia Pharmaceuticals shares today. As a result, investors are bidding the stock up in morning trading.
- 10/10/2023
|
2 Growth Stocks I'd Buy on the Dip
- September hasn't been overly kind to growth stocks. This latest bout of volatility, however, may have created some compelling buying opportunities.
- 09/30/2023
|
Acadia (ACAD) Surges 8.3%: Is This an Indication of Further Gains?
- Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 09/28/2023
|
Acadia stock price analysis: ACAD risk/reward is attractive
- Acadia Pharmaceuticals (NASDAQ: ACAD) stock price did well on Wednesday even as American equities retreated. The biotech stock jumped to a high of $26.15, much higher than this week's low of $22.95.
- 09/27/2023
|
Acadia Pharmaceuticals: Difficult Market Masks Progress
- Acadia Pharmaceuticals' gains recently disappeared despite the strong launch of Daybue. Poor market conditions are to blame, especially the poor biotech investor sentiment. Daybue's sales in Q2 exceeded expectations, with Q3 sales expected to be in the $45-55 million range.
- 09/26/2023
|
Daybue Drives Acadia Pharmaceuticals To Positive Earnings (Rating Upgrade)
- Acadia Pharmaceuticals shows fiscal resilience with a shift to net positive income, buoyed by Daybue's strong Q2 debut and increased Nuplazid sales. Daybue targets a high-need area in Rett syndrome, showing rapid market penetration and potential for substantial long-term revenue streams. Investment Recommendation: Shift stance to "Buy" as Daybue's market promise and Acadia's prudent capital allocation suggest a high-impact, sustainable investment opportunity.
- 09/23/2023
|
2 Supercharged Growth Stocks Billionaires Can't Stop Buying
- Baker Bros. Advisors has been steadily buying Acadia Pharmaceuticals and Roivant Sciences this year.
- 08/28/2023
|
Can This Red-Hot Biotech Stock Keep Beating the Broader Markets?
- Not many stocks can beat the broader market over the long haul. Acadia Pharmaceuticals, a central nervous disorder specialist, may have what it takes.
- 08/22/2023
|
This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street
- Developmental biotechs can deliver outstanding returns for risk-tolerant investors. Wall Street is exceptionally bullish on Stoke Therapeutics, a clinical-stage company developing RNA-based medicines.
- 08/16/2023
|
Here's Why Acadia (ACAD) Looks Ripe for Bottom Fishing
- After losing some value lately, a hammer chart pattern has been formed for Acadia (ACAD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- 08/10/2023
|
FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss
- FATE reports a lower-than-expected loss on a decline in operating expenses in the second quarter of 2023.
- 08/09/2023
|
Acadia (ACAD) Q2 Earnings & Revenues Beat Estimates, '23 View Up
- Acadia (ACAD) reports better-than-expected second-quarter 2023 results, raising its financial guidance for the year. The company also provides updates on its pipeline.
- 08/03/2023
|
Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates
- Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to loss of $0.21 per share a year ago.
- 08/02/2023
|
GSK Gears Up for Q2 Earnings: Will It Surpass Estimates?
- We expect GSK's specialty products like Cabenuva, Dovato, Bexsero, Breo Ellipta and Shingrix to drive second-quarter sales performance.
- 07/21/2023
|
Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large Moves
- Shares of ACADIA Pharmaceuticals Inc. NASDAQ: ACAD jumped nearly 25% on Friday after the San Diego-based company announced preliminary second-quarter results and a pivotal acquisition. The gain was the biggest among all mid- and large cap stocks on the day and more than double that of the next closest winner.
- 07/18/2023
|
Acadia Pharmaceuticals Rights Deal and Bullish Outlook Sends Shares Surging 16%. Here's What to Expect.
- In a stunning two-day rally, shares of Acadia Pharmaceuticals (US:ACAD) have seen a 16% surge following the announcement of the company's acquisition of expanded commercial rights for the groundbreaking Rett syndrome drug, trofinetide.
- 07/17/2023
|
Acadia (ACAD) Soars 24.7%: Is Further Upside Left in the Stock?
- Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
- 07/17/2023
|
Why Acadia Pharmaceuticals Stock Is Soaring Today
- Acadia has acquired expanded rights to two drugs. The company also provided encouraging preliminary Q2 sales figures for its two approved products.
- 07/14/2023
|
Acadia (ACAD) Expands Existing Licensing Deal With Neuren
- Acadia (ACAD) rises 23% for extending its existing licensing agreement with Neuren to include ex-North American rights to trofinetide along with the global rights to a different developmental candidate.
- 07/14/2023
|
Why These 2 Biotech Stocks Made Big Moves Late Thursday
- Stock markets kept climbing on Thursday. Acadia stock moved higher as the company expanded a key licensing agreement.
- 07/13/2023
|
Acadia Pharmaceuticals stock rockets 30% following expanded drug rights
- Acadia Pharmaceuticals Inc. ACAD, -0.23% shares rallied in the extended session Thursday after the drug maker said it expanded its rights to a treatment for a rare neurological disorder. Acadia shares rallied as much as 30% after hours, following a 0.2% decline to close the regular session at $25.80.
- 07/13/2023
|
Acadia (ACAD) to Begin Study on ACP-101 for Hyperphagia in PWS
- Acadia (ACAD) is set to begin a pivotal study evaluating a new developmental candidate, ACP-101, in the treatment of hyperphagia associated with Prader-Willi syndrome.
- 06/14/2023
|
Acadia (ACAD) Up 12% Since Last Earnings Report: Can It Continue?
- Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
- 06/07/2023
|
Acadia Pharmaceuticals (ACAD) Q1 Earnings & Sales Miss Estimates
- Acadia Pharmaceuticals (ACAD) reports weaker-than-expected first-quarter 2023 results as its earnings and revenues miss the Zacks Consensus Estimate. Management maintains its guidance for 2023.
- 05/09/2023
|
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2023 Earnings Call Transcript
- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Mark Johnson - Vice President of Investor Relations Steve Davis - Chief Executive Officer Brendan Teehan - Chief Operating Officer, Head of Commercial Doug Williamson - Head of Research & Development Mark Schneyer - Chief Financial Officer Kathie Bishop - Chief Scientific Officer and Head of Rare Diseases Conference Call Participants Ritu Baral - TD Cowen Charles Duncan - Cantor Fitzgerald Tessa Romero - J.P. Morgan Tazeen Ahmad - Bank of America Neena Bitritto-Garg - Citi Rudy Li - SVB Securities Gregory Renza - RBC Capital Markets Jason Butler - JMP Jeff Hung - Morgan Stanley Yatin Suneja - Guggenheim Operator Good day, ladies and gentlemen.
- 05/08/2023
|
Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates
- Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.70 per share a year ago.
- 05/08/2023
|
4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates
- We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.
- 04/24/2023
|
Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 22nd Annual Needham Virtual Healthcare conference on Tuesday, April 18, 2023 at 1:30 p.m. Eastern Time. The conference will be held virtually. A live webcast of the presentation will be accessible on the company's website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.
- 04/11/2023
|
Strength Seen in Acadia (ACAD): Can Its 5.0% Jump Turn into More Strength?
- Acadia (ACAD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- 03/15/2023
|
Acadia's rare-disease drug to cost $575,000 to $595,000
- Acadia Pharmaceuticals Inc. ACAD said its newly approved treatment for Rett syndrome has an annual list price ranging from $575,000 to $595,000, according to a company spokesperson. The Food and Drug Administration on Friday approved Daybue, the first therapy to treat Rett syndrome, a rare disease that has been diagnosed in 4,500 adults and children in the U.S. The company said it expects to have the drug available in the U.S. by the end of April.
- 03/13/2023
|
Acadia (ACAD) Gets FDA Approval for Daybue for Rett Syndrome
- Acadia Therapeutics (ACAD) announces the FDA approval of its Rett Syndrome drug, trofinetide, for the treatment of adult and pediatric patients two years of age and older. Going to be marketed as Daybue in the United States.
- 03/13/2023
|
3 Nasdaq Stocks on Watch This Week
- Market volatility seems to be the central theme for stocks heading into next week. These three Nasdaq-listed stocks may be among the most volatile.
- 03/12/2023
|
1 Top Biotech Stock to Buy in March
- Acadia Pharmaceuticals expects to learn the regulatory fate of its Rett syndrome candidate on March 12. This rare disease drug could drive the stock up by 21% or higher in the coming days.
- 03/07/2023
|
ACADIA Pharmaceuticals Inc. (ACAD) Q4 2022 Earnings Call Transcript
- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Mark Johnson - Vice President, Investor Relations Steve Davis - Chief Executive Officer Mark Schneyer - Chief Financial Officer Brendan Teehan - Chief Operating Officer, Head, Commercial Kathie Bishop - Chief Scientific Officer and Head, Rare Disease Doug Williamson - Head, Research and Development Conference Call Participants Ritu Baral - Cowen Tessa Romero - J.P. Morgan Marc Goodman - SVB Leerink Tazeen Ahmad - Bank of America Merrill Lynch Charles Duncan - Cantor Fitzgerald Neena Bitritto-Garg - Citi Eddie Hickman - Guggenheim Partners Gregory Renza - RBC Capital Jeff Hung - Morgan Stanley Jay Olson - Oppenheimer David Hoang - SMBC Nikko Kyle Qian - Canaccord Genuity Operator Good day, ladies and gentlemen.
- 02/27/2023
|
Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Tops Revenue Estimates
- Acadia (ACAD) delivered earnings and revenue surprises of -4% and 1.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/27/2023
|
Acadia Pharmaceuticals: What's Ahead In 2023
- Today, we are circling back on mid-cap biopharma ACADIA Pharmaceuticals Inc. for the first time since the spring of 2021. The company had one major disappointment in 2022, but has some potential new drug approvals on the horizon.
- 01/16/2023
|
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
- SAN DIEGO--( BUSINESS WIRE )--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00 a.m. Pacific Time, followed by a question and answer session.
- 12/21/2022
|
Acadia (ACAD) Up 3.5% Since Last Earnings Report: Can It Continue?
- Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
- 12/02/2022
|
Acadia Pharmaceuticals: I Remain Cautiously Bullish After Q3 Updates
- Acadia released its Q322 earnings this week. Revenues of $131m and a net loss of $27.2m are about par for the course. Acadia's only approved drug Nuplazid is approved to treat Parkinson's Disease Psychosis. Several attempts to expand the label have not succeeded.
- 11/04/2022
|
ACADIA Pharmaceuticals, Inc. (ACAD) Q3 2022 Earnings Call Transcript
- ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Mark Johnson - VP, IR Stephen Davis - CEO & Director Brendan Teehan - EVP, COO & Head, Commercial Kathie Bishop - SVP and Head, Rare Disease & External Innovation Srdjan Stankovic - President Mark Schneyer - EVP & CFO Conference Call Participants Jeff Hung - Morgan Stanley Neena Bitritto-Garg - Citi Ritu Baral - Cowen and Company Salveen Richter - Goldman Sachs Jay Olson - Oppenheimer Alex Nackenoff - Raymond James & Associates Marc Goodman - SVB Securities Gregory Renza - RBC Capital Markets Yatin Suneja - Guggenheim Securities Charles Duncan - Cantor Fitzgerald Sumant Kulkarni - Canaccord Genuity Operator Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals Third Quarter 2022 Financial Results Conference Call. My name is Gigi, and I will be your coordinator for today.
- 11/02/2022
|
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Misses Revenue Estimates
- Acadia (ACAD) delivered earnings and revenue surprises of 5.56% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/02/2022
|
Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2022 financial results on Wednesday, November 2, 2022, after the close of the U.S. financial markets.
- 10/20/2022
|
Acadia (ACAD) Rises More Than 14% in 3 Months: Here's Why
- Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, is driving revenues. Other candidates are also making good progress.
- 10/06/2022
|
Why Acadia Pharmaceuticals Stock's Rally Could Have Legs
- Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) is up 3.3% to trade at $17.60 at last check, as the broader market looks to extend its early October rally.
- 10/04/2022
|
Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review
- The FDA accepts and grants priority review to Acadia's (ACAD) NDA for trofinetide to treat Rett syndrome. A decision from the regulatory body is due on Mar 12, 2023.
- 09/13/2022
|
Acadia (ACAD) Down 0.6% Since Last Earnings Report: Can It Rebound?
- Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
- 09/07/2022
|
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences: Citi's 17th Annual BioPharma Conference Fireside Chat: Thursday, September 8, 2022 at 1:00 p.m. Eastern Time in Boston, MA Morgan Stanley 20th Annual Global Healthcare Conference Fireside Chat: Tuesday, September 13, 2022 at 11:10 a.m. Eastern Time in New York, NY Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Virtual Summit Firesi
- 09/01/2022
|
Acadia (ACAD) Upgraded to Buy: What Does It Mean for the Stock?
- Acadia (ACAD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 08/26/2022
|
Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates
- Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.
- 08/09/2022
|
ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q2 2022 Results - Earnings Call Transcript
- ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Kathie Bishop - SVP and Head, Rare Disease & External Innovation Srdjan Stankovic - President Stephen Davis - CEO & Director Mark Johnson - VP, IR Brendan Teehan - EVP, COO & Head of Commercial Mark Schneyer - EVP & CFO Conference Call Participants Jay Olson - Oppenheimer Marc Goodman - SVB Securities Tazeen Ahmad - Bank of America Merrill Lynch Ritu Baral - Cowen and Company Neena Garg - Citigroup Gregory Renza - RBC Capital Markets Sumant Kulkarni - Canaccord Genuity Charles Duncan - Cantor Fitzgerald & Co. Eddie Hickman - Guggenheim Securities Operator Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals Second Quarter 2022 Financial Results Conference Call. [Operator Instructions].
- 08/08/2022
|
Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates
- Acadia (ACAD) delivered earnings and revenue surprises of 16% and 2.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/08/2022
|
Acadia: Powerful Unfolding Catalysts
- Aside from being launched for Parkinson's, Nuplazid is potentially gaining two additional label expansions. Trofinetide is also poised to gain FDA approval to treat the rare condition, Rett syndrome as early as 1Q 2023.
- 08/03/2022
|
Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/01/2022
|
Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on August 8, 2022, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call may be accessed by registering for the call here. Once registered, participants will receive an emai
- 07/25/2022
|
Acadia (ACAD) Files an NDA for Its Rett Syndrome Candidate
- Acadia (ACAD) submits a new drug application to the FDA for trofinetide to treat Rett syndrome in patients aged two and older.
- 07/19/2022
|
Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why
- The recent setback faced by Acadia's (ACAD) resubmitted sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with ADP has hurt the stock.
- 07/08/2022
|
FDA AdComm Rejects Nuplazid This Time But Acadia's Race Isn't Run Yet
- Acadia won approval for its only commercialized drug Nuplazid in 2017 and has tried and failed to expand its label since. This month an FDA AdComm voted against an approval in Alzheimer's disease psychosis, despite the FDA issuing positive briefing notes.
- 06/29/2022
|
3 Big Ideas From Citigroup With Up to 80% Upside
- As markets figure out a direction over the course of this summer, economic headwinds may be holding back some gains.
- 06/22/2022
|
Why Is Acadia Pharmaceuticals (ACAD) Stock Down 33% Today?
- Today, investors in Acadia Pharmaceuticals and ACAD stock are in selling mode. The FDA gave a thumbs down on a key drug.
- 06/21/2022
|
Why Acadia Pharmaceuticals Stock Is Crashing Today
- An FDA advisory committee voted against recommending approval for pimavanserin in treating Alzheimer's disease psychosis.
- 06/21/2022
|
Biotech Stock Plummets After FDA Snub
- Acadia Pharmaceuticals Inc (NASDAQ:ACAD) stock is one of the worst stocks on the Nasdaq today, down 35.6% to trade at $12.56 at last check.
- 06/21/2022
|
Why Acadia Pharma Shares Are Plunging Today
- A panel of the FDA's outside experts voted 9-3 that Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin doesn't appear to be effective at treating patients with Alzheimer's-related psychosis. The drug, Nuplazid, is already indicated for Parkinson's-.
- 06/21/2022
|
FDA Panel Votes Against Acadia (ACAD) sNDA for Nuplazid
- An FDA advisory committee votes against Acadia's (ACAD) Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis.
- 06/20/2022
|
Acadia Pharmaceuticals stock halted for FDA panel to review treatment for hallucinations stemming from Alzheimer's disease psychosis
- Acadia Pharmaceuticals Inc. ACAD, +3.94% said Friday its stock will be halted from trading Friday as a U.S. Food and Drug Administration panel meets virtually to discuss a new drug application for a treatment for hallucinations and delusions associated with Alzheimer's disease psychosis. The FDA's Psychopharmacologic Drugs Advisory Committee will review Acadia's Nuplazid at a meeting scheduled for 8:45 a.m.
- 06/17/2022
|
HC Wainwright Sees Opportunity For Acadia's Alzheimer's Candidate
- HC Wainwright says FDA's briefing document on ACADIA Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin was not unexpected. It reiterates the stock with a Buy rating and a price target of $36.00.
- 06/16/2022
|
Acadia (ACAD) Up on FDA Briefing Document for Nuplazid sNDA
- The FDA issues briefing documents related to Acadia's (ACAD) resubmitted sNDA for Nuplazid for treating hallucinations and delusions associated with Alzheimer's disease psychosis. Shares rise.
- 06/16/2022
|
Acadia (ACAD) Surges 15.5%: Is This an Indication of Further Gains?
- Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 06/16/2022
|
Why ACADIA Pharmaceuticals Shares Are Trading Higher Today?
- Ahead of Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) FDA AdComm meeting on Friday, the agency officials released their briefing documents, revealing a mixed bag of opinions. The company's resubmitted supplemental New Drug Application for pimavanserin for hallucinations.
- 06/15/2022
|
Why Acadia Pharmaceuticals Spiked Today
- Regulators might be warming to the company's candidate to treat Alzheimer's-associated psychosis.
- 06/15/2022
|
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
- Biotech investors stand to make a windfall if they make calculated bets by thoroughly researching on key catalysts that could move the stocks in a big way. The post 6 Biotech Stocks to Buy Now Ahead of These June Catalysts appeared first on InvestorPlace.
- 06/03/2022
|
Why Is Acadia (ACAD) Down 13.9% Since Last Earnings Report?
- Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
- 06/03/2022
|
Alzamend Neuro to Present at the 12th Annual LD Micro Invitational
- ATLANTA--(BUSINESS WIRE)---- $ACAD #ACImmune--Alzamend Neuro to Present at 12th Annual LD Micro Invitational Investor Conference; Focuses on Progress with Clinical Trials & INDs for AL001 & AL002
- 06/03/2022
|
ACADIA Pharmaceuticals Inc. (ACAD) CEO Stephen Davis on Q1 2022 Results - Earnings Call Transcript
- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Mark Johnson - VP, IR Stephen Davis - CEO Brendan Teehan - COO and Head, Commercial Mark Schneyer - CFO Serge Stankovic - President Conference Call Participants Charles Duncan - Cantor Fitzgerald Neena Bitritto-Garg - Citi Gregory Renza - RBC Capital Markets Yatin Suneja - Guggenheim Partners Sumant Kulkarni - Canaccord David Hoang - SMBC Rudy Li - SVB Securities Chris Howerton - Jefferies Vamil Divan - Mizuho Securities Alex Thompson - Stifel Jay Olson - Oppenheimer Esther Hong - Berenberg Operator Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals First Quarter 2022 Financial Results Conference Call. My name is Crystal and I'll be your coordinator for today.
- 05/04/2022
|
Acadia: Catalysts Stacking
- The lead drug (Nuplazid) is enjoying aggressive sales growth and thereby trumping competitors. In taking success to the next level, Acadia is expanding Nuplazid's label for schizophrenia and Alzheimer's psychosis.
- 04/28/2022
|
Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for
- Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/27/2022
|
Acadia (ACAD) Stock Down as Pain Candidate Misses Study Goal
- Acadia's (ACAD) phase II study, evaluating ACP-044 for treating acute pain following bunionectomy surgery, misses the primary endpoint. Stock down.
- 04/19/2022
|
Why Is Acadia (ACAD) Up 1% Since Last Earnings Report?
- Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
- 03/30/2022
|
Wednesday Top Stock News: 8 Analyst Upgrades and Downgrades Today
- We're taking a look at the top stock news for Wednesday and that includes the latest analysts upgrades and downgrades you need to know about! The post Wednesday Top Stock News: 8 Analyst Upgrades and Downgrades Today appeared first on InvestorPlace.
- 03/16/2022
|
Acadia (ACAD) Stock Up on FDA's Action Date for Nuplazid sNDA
- Acadia (ACAD) gets an action date of Aug 4, 2022, from the FDA for its resubmitted sNDA for pimavanserin to treat hallucinations and delusions associated with Alzheimer's disease psychosis.
- 03/10/2022
|
Why Acadia Healthcare (ACHC) Stock Might be a Great Pick
- Acadia Healthcare (ACHC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 03/08/2022
|
Acadia Healthcare (ACHC) is a Top-Ranked Momentum Stock: Should You Buy?
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 03/07/2022
|
Acadia (ACAD) Q4 Earnings & Revenues Fall Shy of Estimates
- Acadia (ACAD) posts a wider-than-expected loss for the fourth quarter of 2021. Shares fall during the after-hours trading.
- 03/01/2022
|
ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q4 2021 Results - Earnings Call Transcript
- ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q4 2021 Results - Earnings Call Transcript
- 02/28/2022
|
Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Lags Revenue Estimates
- Acadia (ACAD) delivered earnings and revenue surprises of -12.50% and 3.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/28/2022
|
Acadia's NUPLAZID, FDA's Second Chance To Get Alzheimer's Right
- Acadia's NUPLAZID, FDA's Second Chance To Get Alzheimer's Right
- 02/22/2022
|
Will Acadia Pharmaceuticals (ACAD) Report Negative Earnings Next Week? What You Should Know
- Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/21/2022
|
Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022, at 1:40 p.m. Eastern Time. The conference will be held virtually. A live webcast of Acadia's presentation will be accessible on the company's website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through March 18, 2022. About Acadia Phar
- 02/11/2022
|
Acadia (ACAD) Up More Than 20% in Past 3 Months: Here's Why
- Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, has seen strong uptake so far. Its label expansion studies also hold promise.
- 01/13/2022
|
Acadia (ACAD) Partners With Stoke for CNS Disorder Therapies
- Acadia (ACAD) signs a collaboration agreement with Stoke Therapeutics to develop/commercialize RNA-based medicines for addressing genetic neurodevelopmental diseases.
- 01/11/2022
|
Will Acadia Pharmaceuticals Stock See Higher Levels After A Large 26% Rally In A Month?
- The stock of Acadia Pharmaceuticals (NASDAQ: ACAD), a biopharmaceutical company focused on neuroscience drugs, has seen a rise of 26% over the last month. ACAD stock rose from levels of around $19 in early December to levels of $27 on December 20, before cooling off to levels of $24 currently.
- 01/06/2022
|
5 Beaten Down Biotech Stocks That Could Bounce Big In 2022
- Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in programs and the reemergence of variant strains.
- 12/27/2021
|
Why Acadia Pharmaceuticals Stock Climbed More Than 10% Wednesday
- The biotech saw a rebound after a down day on Tuesday.
- 12/22/2021
|
What Analysts Have To Say On Acadia's Narrower Nuplazid Label Expansion Bid
- RBC Capital raised the price target on Acadia Pharmaceuticals Inc (NASDAQ:ACAD) to $34 from $32 and kept an Outperform rating on the shares. Analyst Gregory Renza cites the Company's confirmed intentions to resubmit the sNDA filing of pimavanserin in Alzheimer's Disease Psychosis, with a "narrower though still robust opportunity" as the largest subtype of DRP.
- 12/21/2021
|
ACADIA (ACAD) Up on Resubmission Plan for Nuplazid sNDA to FDA
- ACADIA (ACAD) to resubmit sNDA for Nuplazid (pimavanserin) to the FDA for treating hallucinations and delusions associated with dementia focused on Alzheimer's disease psychosis. Shares rise.
- 12/21/2021
|
Acadia Pharma Shares Jump on Positive Test Results for Rett's Drug
- Acadia Pharmaceuticals Inc. ( ACAD , Financial) investors finally got some good news this week when the biopharma announced positive test results for its treatment for a rare neurological condition.
- 12/08/2021
|
Acadia: Big News On The Near Horizon
- Acadia reported solid earnings for Q3, 2021 despite COVID-19 headwind lashing its Parkinson's Disease Psychosis [PDP] earnings. Acadia's completed Type A Meeting with the FDA has opened the door for a targeted next step.
- 12/08/2021
|
Good Stocks To Invest In Right Now? 4 Health Care Stocks To Check Out
- While markets are cautiously optimistic on the Omicron variant, these health care stocks are still hard at work.
- 12/07/2021
|
ACADIA's (ACAD) Rett Syndrome Candidate Meets Goal in Study
- ACADIA's (ACAD) phase III study, evaluating the efficacy and safety of trofinetide in patients with Rett syndrome, meets co-primary endpoints. Shares rise.
- 12/07/2021
|
Acadia Pharmaceuticals Stock (ACAD): Why The Price Jumped Today
- The stock price of Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) increased by over 15% pre-market today. This is why it happened.
- 12/07/2021
|
Why Acadia Pharmaceuticals Stock Is Rocketing Today
- A positive clinical readout is lighting a fire underneath the biotech's shares today.
- 12/07/2021
|
Acadia Pharma Jumps After Rett Syndrome Candidate Aces Phase 3 Study
- Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced topline results from Phase 3 Lavender study of trofinetide in Rett syndrome. The 12-week study demonstrated a statistically significant improvement over placebo for both co-primary endpoints.
- 12/07/2021
|
Why Seasoned Investors are Retaining Acadia (ACHC) Stock
- Acadia Healthcare's (ACHC) buyouts are helping the company to add facilities, beds and hospitals to its network and contributing to its top line.
- 11/30/2021
|
ACADIA Pharmaceuticals (ACAD) CEO Stephen Davis on Q3 2021 Results - Earnings Call Transcript
- ACADIA Pharmaceuticals (ACAD) CEO Stephen Davis on Q3 2021 Results - Earnings Call Transcript
- 11/08/2021
|
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates
- Acadia (ACAD) delivered earnings and revenue surprises of 66.67% and 3.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/08/2021
|
4 Healthcare Stocks to Top Q3 Estimates Amid Coronavirus Woes
- Factors like an aging populace and demand for products and services are likely to reflect on the Q3 results of ACAD, MD, ACHC and VRTX.
- 10/26/2021
|
Neurocrine, ACADIA: Fast Growing Health Care Stocks That Are Underperforming
- Our theme of Out Of Favor Health Care Stocks includes biotech and pharma names that are seeing a disconnect between their recent financial performance and recent stock price returns. The theme remains down by about 35% year-to-date, compared to the S&P 500 which is up by a solid 21%.
- 10/26/2021
|
3 Biotech Stocks to Watch Now
- Biotech companies develop new medicines, vaccines, or medical devices. They use advanced technologies and medical science to do so.
- 10/12/2021
|
Can These Former Biotech Growth Stocks Regain Their Form?
- Acadia Pharmaceuticals and Clovis Oncology may be turnaround stories in the making.
- 09/29/2021
|
Acadia Pharmaceuticals: Refunding A Former Champion
- Acadia Pharmaceuticals: Refunding A Former Champion
- 09/29/2021
|
How Does Acadia Stock Performance In The Current Crisis Compare With That In 2008?
- We believe that Acadia Pharmaceuticals stock, a biopharmaceutical company focused on neuroscience drugs, is a good buying opportunity at the present time. ACAD stock trades around $17 levels currently and it is, in fact, down 64% from its pre-Covid high of around $47 in February 2020.
- 09/08/2021
|
Acadia Pharmaceuticals Announces Executive Leadership Change
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Elena Ridloff, Executive Vice President and Chief Financial Officer (CFO), will be leaving the company effective September 10, 2021 to join another biopharmaceutical company. Mark Schneyer, Senior Vice President, Business Development and Chief Business Officer, will serve as Acadia's interim Chief Financial Officer. The company is conducting a formal search for a new CFO. “On behalf of all of us at Acadi
- 09/01/2021
|
Why Acadia Healthcare (ACHC) Stock Might be a Great Pick
- Acadia Healthcare (ACHC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 08/25/2021
|
ACADIA (ACAD) Q2 Earnings Beat, Revenues Miss Estimates
- ACADIA's (ACAD) loss narrows in the second quarter of 2021 while its revenues miss the mark. The company has reduced its revenue guidance for 2021.
- 08/05/2021
|
4 Bullish Stock Picks After Earnings With Huge Potential Upside
- Earnings season is winding down. With that come analyst projections for where these stocks and the market in general could go in the coming months.
- 08/05/2021
|
ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q2 2021 Results - Earnings Call Transcript
- ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q2 2021 Results - Earnings Call Transcript
- 08/05/2021
|
Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Misses Revenue Estimates
- Acadia (ACAD) delivered earnings and revenue surprises of 10.00% and -9.27%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2021
|
Acadia Healthcare's (ACHC) Solid Results Lead to Stock Rally
- Acadia Healthcare Company (ACHC) gains from rising demand for its behavioral healthcare services and investors' optimism on clarity about its growth strategies.
- 08/04/2021
|
The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the New England Journal of Medicine published results from the Phase 3 HARMONY study, an international, double-blind, placebo-controlled relapse prevention trial in 392 patients evaluating pimavanserin as an investigational treatment in patients with hallucinations and delusions associated with dementia-related psychosis (DRP). The study included patients across five subgroups of dementia: Alzheimer's di
- 07/21/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 21, 2021 - ACAD
- New York, New York--(Newsfile Corp. - June 21, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get...
- 06/21/2021
|
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 21, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 15, 2020 and April 4, 2021, inclusive...
- 06/21/2021
|
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $ACAD #ACAD--DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.
- 06/20/2021
|
ACAD INVESTOR DEADLINE MONDAY: Hagens Berman Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm Now
- San Francisco, California--(Newsfile Corp. - June 19, 2021) - Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now.Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 21, 2021Visit: www.hbsslaw.com/investor-fraud/ACADContact An Attorney Now: ACAD@hbsslaw.com844-916-0895Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Securities Fraud Action:The complaint alleges that Defendants misrepresented facts concerning Acadia's supplemental new drug application
- 06/19/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD
- New York, New York--(Newsfile Corp. - June 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more...
- 06/18/2021
|
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 18, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 15, 2020 and April 4, 2021, inclusive...
- 06/18/2021
|
Final Deadline for Investors to Actively Participate in ACADIA Pharmaceuticals Inc. (ACAD) Class Action: Bronstein, Gewirtz & Grossman, LLC
- New York, New York--(Newsfile Corp. - June 18, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. ("ACADIA" or "the Company") (NASDAQ: ACAD) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired ACADIA securities between June 15, 2020 and April 4, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting...
- 06/18/2021
|
ACAD LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Acadia Pharmaceuticals Inc.
- New York, New York--(Newsfile Corp. - June 17, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?prid=16974&wire=5
- 06/17/2021
|
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 17, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 15, 2020 and April 4, 2021, inclusive...
- 06/17/2021
|
ACAD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Acadia Pharmaceuticals Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - June 17, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) alleging that the Company violated federal securities laws.Class Period: June 15, 2020 and April 4, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in ACAD:
- 06/17/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD
- New York, New York--(Newsfile Corp. - June 16, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more...
- 06/16/2021
|
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)
- LOS ANGELES--(BUSINESS WIRE)---- $ACAD #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)
- 06/16/2021
|
Two Days Left to Actively Participate in ACADIA Pharmaceuticals Inc. (ACAD) Class Action: Bronstein, Gewirtz & Grossman, LLC
- NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. ("ACADIA" or "the Company") (NASDAQ: ACAD) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired ACADIA securities between June 15, 2020 and April 4, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site:
- 06/16/2021
|
FRIDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 16, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 15, 2020 and April 4, 2021, inclusive...
- 06/16/2021
|
FRIDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 15, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 15, 2020 and April 4, 2021, inclusive...
- 06/15/2021
|
Last Few Days to Actively Participate in ACADIA Pharmaceuticals Inc. (ACAD) Class Action: Bronstein, Gewirtz & Grossman, LLC
- New York, New York--(Newsfile Corp. - June 15, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. ("ACADIA" or "the Company") (NASDAQ: ACAD) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired ACADIA securities between June 15, 2020 and April 4, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting...
- 06/15/2021
|
ACAD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Acadia Pharmaceuticals Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - June 14, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) alleging that the Company violated federal securities laws.Class Period: June 15, 2020 and April 4, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in ACAD:
- 06/14/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD
- New York, New York--(Newsfile Corp. - June 14, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more...
- 06/14/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
- New York, New York--(Newsfile Corp. - June 12, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company")(NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 21-cv-00762, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or...
- 06/12/2021
|
ACAD BREAKING ALERT: ROSEN, A LONGSTANDING LAW FIRM, Encourages Acadia Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 18 Deadline in Securities Class Action – ACAD
- NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021, inclusive (the “Class Period”) of the important June 18, 2021 lead plaintiff deadline. SO WHAT: If you purchased Acadia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO
- 06/11/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
- NEW YORK, June 10, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company")(NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 21-cv-00762, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Acadia securities between June 15, 2020 and April 4, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 06/10/2021
|
What 18 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
- Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 0 0 1 Somewhat Bullish 0 0 1 1 Indifferent 1 1 0 5 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 18 analysts offering 12-month price targets in the last 3 months for ACADIA Pharmaceuticals evaluate the company at an average price target of $33.17 with a high of $65.00 and a low of $18.00.
- 06/10/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 10, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 15, 2020 and April 4, 2021, inclusive...
- 06/10/2021
|
UPCOMING DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 9, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 15, 2020 and April 4, 2021, inclusive...
- 06/09/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD
- New York, New York--(Newsfile Corp. - June 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get...
- 06/08/2021
|
ACAD LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Acadia Pharmaceuticals Inc.
- New York, New York--(Newsfile Corp. - June 8, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?prid=16690&wire=5
- 06/08/2021
|
UPCOMING DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 8, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 15, 2020 and April 4, 2021, inclusive...
- 06/08/2021
|
ACAD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Acadia Pharmaceuticals Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - June 8, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) alleging that the Company violated federal securities laws.Class Period: June 15, 2020 and April 4, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in ACAD:
- 06/08/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD
- New York, New York--(Newsfile Corp. - June 7, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more...
- 06/07/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
- New York, New York--(Newsfile Corp. - June 5, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 21-cv-00762, is on behalf of a class consisting of all persons and entities other than Defendants that purchased...
- 06/05/2021
|
Rosen, Global Investor Counsel, Encourages Acadia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important June 18 Deadline in Securities Class Action - ACAD
- New York, New York--(Newsfile Corp. - June 4, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court...
- 06/04/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD
- New York, New York--(Newsfile Corp. - June 3, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get...
- 06/03/2021
|
HAGENS BERMAN Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact its Attorneys Before June 18th Application Deadline in Securities Fraud Lawsuit
- San Francisco, California--(Newsfile Corp. - June 3, 2021) - Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit: www.hbsslaw.com/investor-fraud/ACADContact An Attorney Now: ACAD@hbsslaw.com 844-916-0895Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Securities Fraud Action:The complaint alleges that Defendants misrepresented facts concerning Acadia's supplementa
- 06/03/2021
|
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 3, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 15, 2020 and April 4, 2021, inclusive...
- 06/03/2021
|
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 2, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 15, 2020 and April 4, 2021, inclusive...
- 06/02/2021
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 1, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 15, 2020 and April 4, 2021, inclusive...
- 06/01/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
- NEW YORK, June 1, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 21-cv-00762, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Acadia securities between June 15, 2020 and April 4, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 06/01/2021
|
ACAD LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Acadia Pharmaceuticals Inc.
- New York, New York--(Newsfile Corp. - May 31, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on the behalf of investors who purchased Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?prid=16375&wire=5
- 05/31/2021
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 31, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 15, 2020 and April 4, 2021, inclusive...
- 05/31/2021
|
ACAD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Acadia Pharmaceuticals Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 31, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) alleging that the Company violated federal securities laws.Class Period: June 15, 2020 and April 4, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in ACAD:
- 05/31/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD
- New York, New York--(Newsfile Corp. - May 30, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more...
- 05/30/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
- New York, New York--(Newsfile Corp. - May 29, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company")(NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 21-cv-00762, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or...
- 05/29/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD
- New York, New York--(Newsfile Corp. - May 28, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more...
- 05/28/2021
|
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Acadia Pharmaceuticals Inc. Investors With Losses Over $100K to Secure Counsel Before Important June 18 Deadline in Securities Class Action - ACAD
- NEW YORK, May 28, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed.
- 05/28/2021
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) Investors
- LOS ANGELES, May 28, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD) securities between June 15, 2020 and April 4, 2021 , inclusive (the "Class Period").
- 05/28/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 28, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 15, 2020 and April 4, 2021, inclusive...
- 05/28/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD
- New York, New York--(Newsfile Corp. - May 27, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more...
- 05/27/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 27, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 15, 2020 and April 4, 2021, inclusive...
- 05/27/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD
- New York, New York--(Newsfile Corp. - May 25, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more...
- 05/25/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
- NEW YORK, May 25, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company")(NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 21-cv-00762, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Acadia securities between June 15, 2020 and April 4, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 05/25/2021
|
HAGENS BERMAN Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, Securities Class Action Pending, June Deadline Approaching
- San Francisco, California--(Newsfile Corp. - May 24, 2021) - Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit: www.hbsslaw.com/investor-fraud/ACADContact An Attorney Now: ACAD@hbsslaw.com 844-916-0895Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Securities Fraud Action:The complaint alleges that Defendants misrepresented facts concerning Acadia's supplemental
- 05/24/2021
|
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)
- BENSALEM, Pa., May 24, 2021 /PRNewswire/ -- Law Offices of Howard G.
- 05/24/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
- New York, New York--(Newsfile Corp. - May 22, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 21-cv-00762, is on behalf of a class consisting of all persons and entities other than Defendants that purchased...
- 05/22/2021
|
ACAD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Acadia Pharmaceuticals Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 21, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) alleging that the Company violated federal securities laws.Class Period: June 15, 2020 and April 4, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in ACAD:
- 05/21/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD
- New York, New York--(Newsfile Corp. - May 20, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more...
- 05/20/2021
|
HAGENS BERMAN Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, Securities Fraud Class Action Filed
- San Francisco, California--(Newsfile Corp. - May 20, 2021) - Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit: www.hbsslaw.com/investor-fraud/ACADContact An Attorney Now: ACAD@hbsslaw.com 844-916-0895Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Securities Fraud Action:The complaint alleges that Defendants misrepresented facts concerning Acadia's supplemental
- 05/20/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
- NEW YORK, May 18, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company")(NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 21-cv-00762, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Acadia securities between June 15, 2020 and April 4, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 05/18/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm to Recover Losses Due to Alleged Securities Fraud
- San Francisco, California--(Newsfile Corp. - May 17, 2021) - Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now.Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit: www.hbsslaw.com/investor-fraud/ACADContact An Attorney Now: ACAD@hbsslaw.com844-916-0895Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Securities Fraud Action:The complaint alleges that Defendants misrepresented facts concerning Acadia's supplemental new drug application ("
- 05/17/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD
- New York, New York--(Newsfile Corp. - May 13, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more...
- 05/13/2021
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)
- LOS ANGELES, May 13, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming June 18, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD) securities between June 15, 2020 and April 4, 2021 , inclusive (the "Class Period"). If you suffered a loss on your Acadia investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/acadia-pharmaceuticals-inc/.
- 05/13/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
- NEW YORK, May 13, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 21-cv-00762, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Acadia securities between June 15, 2020 and April 4, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 05/13/2021
|
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 15, 2020 and April 4, 2021, inclusive...
- 05/12/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD
- New York, New York--(Newsfile Corp. - May 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more...
- 05/11/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD
- New York, New York--(Newsfile Corp. - May 6, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more...
- 05/06/2021
|
ACADIA (ACAD) Q1 Earnings Beat, Revenues Fall Shy of Estimates
- ACADIA's (ACAD) loss narrows in the first quarter of 2021 while its revenues miss the mark. Robust Nuplazid performance drives the top line year over year.
- 05/06/2021
|
ACAD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Acadia Pharmaceuticals Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 6, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) alleging that the Company violated federal securities laws.Class Period: June 15, 2020 and April 4, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in ACAD:
- 05/06/2021
|
ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q1 2021 Results - Earnings Call Transcript
- ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q1 2021 Results - Earnings Call Transcript
- 05/05/2021
|
Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates
- Acadia (ACAD) delivered earnings and revenue surprises of 20.75% and -5.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD
- New York, New York--(Newsfile Corp. - May 5, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more...
- 05/05/2021
|
ACAD DEADLINE: HAGENS BERMAN, National Trial Attorneys, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action, Advises Investors with Losses to Contact Its Attorneys Now
- San Francisco, California--(Newsfile Corp. - May 5, 2021) - Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit: www.hbsslaw.com/investor-fraud/ACADContact An Attorney Now: ACAD@hbsslaw.com 844-916-0895Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Securities Fraud Action:The complaint alleges that Defendants misrepresented facts concerning Acadia's supplemental new drug appli
- 05/05/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
- New York, New York--(Newsfile Corp. - May 5, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 21-cv-00762, is on behalf of a class consisting of all persons and entities other than Defendants that purchased...
- 05/05/2021
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) Investors
- LOS ANGELES, May 4, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD) securities between June 15, 2020 and April 4, 2021 , inclusive (the "Class Period").
- 05/04/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD
- New York, New York--(Newsfile Corp. - May 3, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more...
- 05/03/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
- NEW YORK, May 2, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company")(NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 21-cv-00762, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Acadia securities between June 15, 2020 and April 4, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 05/02/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD
- New York, New York--(Newsfile Corp. - April 29, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more...
- 04/29/2021
|
ACAD INVESTOR DEADLINE: HAGENS BERMAN, National Trial Attorneys, Advises Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed
- San Francisco, California--(Newsfile Corp. - April 29, 2021) - Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now.Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit: www.hbsslaw.com/investor-fraud/ACADContact An Attorney Now: ACAD@hbsslaw.com844-916-0895Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Securities Fraud Action:The complaint alleges that Defendants misrepresented facts concerning Acadia's supplemental new drug application
- 04/29/2021
|
ACAD Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds ACADIA Pharmaceuticals Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm
- NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. ("ACADIA" or "the Company") (NASDAQ: ACAD) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired ACADIA securities between June 15, 2020 and April 4, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site:
- 04/29/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
- New York, New York--(Newsfile Corp. - April 28, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 21-cv-00762, is on behalf of a class consisting of all persons and entities other than Defendants that purchased...
- 04/28/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD
- New York, New York--(Newsfile Corp. - April 28, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more...
- 04/28/2021
|
Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/28/2021
|
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - April 28, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 15, 2020 and April 4, 2021, inclusive...
- 04/28/2021
|
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)
- BENSALEM, Pa.--(BUSINESS WIRE)---- $ACAD #CLASSACTION--Law Offices of Howard G. Smith reminds investors of the upcoming June 18, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD) securities between June 15, 2020 and April 4, 2021, inclusive (the “Class Period”). Investors suffering losses on their Acadia investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their lega
- 04/28/2021
|
EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages Acadia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline – ACAD
- NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 18, 2021. SO WHAT: If you purchased Acadia securities during the Class Period
- 04/27/2021
|
ACAD LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Acadia Pharmaceuticals Inc.
- New York, New York--(Newsfile Corp. - April 27, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?prid=15185&wire=5
- 04/27/2021
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) Investors
- LOS ANGELES--(BUSINESS WIRE)---- $ACAD #investors--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) Investors
- 04/27/2021
|
ACAD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Acadia Pharmaceuticals Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - April 26, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) alleging that the Company violated federal securities laws.Class Period: June 15, 2020 and April 4, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in ACAD:
- 04/26/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
- NEW YORK, April 26, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 21-cv-00762, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Acadia securities between June 15, 2020 and April 4, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 04/26/2021
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, April 26, 2021 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between June 15, 2020 and April 4, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before June 18, 2021.
- 04/26/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD
- New York, New York--(Newsfile Corp. - April 23, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more...
- 04/23/2021
|
ACAD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Acadia Pharmaceuticals Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - April 23, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) alleging that the Company violated federal securities laws.Class Period: June 15, 2020 and April 4, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in ACAD:
- 04/23/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Pending, Deadline Approaching
- San Francisco, California--(Newsfile Corp. - April 23, 2021) - Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit: www.hbsslaw.com/investor-fraud/ACADContact An Attorney Now: ACAD@hbsslaw.com 844-916-0895Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Securities Fraud Action:The complaint alleges that Defendants misrepresented facts concerning Acadia's supplementa
- 04/23/2021
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $ACAD #ACAD--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.
- 04/23/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD
- New York, New York--(Newsfile Corp. - April 22, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more...
- 04/22/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $ACAD #ACAD--SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.
- 04/22/2021
|
The Law Offices of Frank R. Cruz Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $ACAD #investors--The Law Offices of Frank R. Cruz Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) on Behalf of Investors
- 04/22/2021
|
ACAD Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies ACADIA Pharmaceuticals Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
- NEW YORK, April 22, 2021 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. ("ACADIA" or "the Company") (NASDAQ: ACAD) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired ACADIA securities between June 15, 2020 and April 4, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/acad.
- 04/22/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed
- SAN FRANCISCO, April 22, 2021 /PRNewswire/ -- Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: June 15, 2020 - Apr. 4, 2021 Lead Plaintiff Deadline: June 18, 2021 Visit: www.hbsslaw.com/investor-fraud/ACAD Contact An Attorney Now: ACAD@hbsslaw.com 844-916-0895 Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Securities Fraud Action: The complaint alleges that Defendants misrepresented facts concerning Acadia's supplemental new drug application ("sNDA") for NUPLAZID® (pimavanserin), which treats dementia-related psychosis ("DRP").
- 04/22/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
- New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 21-cv-00762, is on behalf of a class consisting of all persons and entities other than Defendants that purchased...
- 04/21/2021
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) on Behalf of Investors
- BENSALEM, Pa.--(BUSINESS WIRE)---- $ACAD #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD) investors concerning the Company's possible violations of federal securities laws. Acadia is a biopharmaceutical company that develops a drug called pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia, as well as an adjunctive treatment for major depressive disorder. I
- 04/21/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed
- San Francisco, California--(Newsfile Corp. - April 21, 2021) - Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now.Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit: www.hbsslaw.com/investor-fraud/ACADContact An Attorney Now: ACAD@hbsslaw.com844-916-0895Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Securities Fraud Action:The complaint alleges that Defendants misrepresented facts concerning Acadia's supplemental new drug application
- 04/21/2021
|
ACADIA PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Acadia Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)-- #AcadiaPharmaceuticals--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of investors that purchased Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) securities between June 15, 2020 and April 4, 2021, inclusive (the “Class Period”). Investors have until June 18, 2021 to apply to the Court to be appointed as lead plaintiff
- 04/20/2021
|
Pomerantz Law Firm Announces the Filing of a Class Action against Acadia Pharmaceuticals Inc. and Certain Officers - ACAD
- NEW YORK, April 19, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company")(NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 21-cv-00762, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Acadia securities between June 15, 2020 and April 4, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 04/19/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys, Firm Investigating ACAD for Possible Securities Law Violations
- San Francisco, California--(Newsfile Corp. - April 14, 2021) - Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims.Visit: www.hbsslaw.com/investor-fraud/ACADContact An Attorney Now: ACAD@hbsslaw.com 844-916-0895Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Investigation:The investigation focuses on the accuracy of Acadia's disclosures concerning its supplemental new drug applic
- 04/14/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys, Firm Investigation ACAD for Possible Securities Law Violations
- San Francisco, California--(Newsfile Corp. - April 8, 2021) - Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims.Visit: www.hbsslaw.com/investor-fraud/ACADContact An Attorney Now: ACAD@hbsslaw.com844-916-0895Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Investigation:The investigation focuses on the accuracy of Acadia's disclosures concerning its supplemental new drug application ("
- 04/08/2021
|
After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock Drivers
- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares came under pressure Monday after the Food and Drug Administration (FDA) rejected its regulatory application seeking label expansion for its dementia drug. The Acadia Analysts: Goldman Sachs analyst Salveen Richter downgraded Acadia shares from Buy to Neutral and cut the price target from $73 to $25.
- 04/06/2021
|
ACADIA (ACAD) Gets CRL From FDA for Nuplazid sNDA, Shares Down
- The FDA issues a Complete Response Letter to ACADIA's (ACAD) sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with dementia-related psychosis. Stock falls.
- 04/06/2021
|
ACADIA Pharmaceuticals Stock Price: $28 Target (Down From $50) By Morgan Stanley
- The shares of ACADIA Pharmaceuticals (NASDAQ: ACAD) have received a decreased price target from $50 to $28. These are the details.
- 04/06/2021
|
Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc.
- MILWAUKEE, April 6, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Acadia (NASDAQ: ACAD). The investigation results from inaccurate statements Acadia may have made regarding its financial results, business operations and prospects.
- 04/06/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys
- SAN FRANCISCO, April 5, 2021 /PRNewswire/ -- Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims.
- 04/05/2021
|
Why Acadia Pharma, Bio-path And Cidara Are Moving Today
- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and Cidara Therapeutics, Inc. (NASDAQ: CDTX) are among the early movers in the biotech space. ACADIA Wilts On FDA Rejection: Acadia said the FDA has issued a complete response letter regarding its supplemental new drug application for Nuplazid for the treatment of hallucinations and delusions associated with dementia-related psychosis.
- 04/05/2021
|
ACADIA Pharmaceuticals Stock Price Fell Over 19% Pre-Market: Why It Happened
- The stock price of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) fell by over 19% pre-market. This is why it happened.
- 04/05/2021
|
Acadia Stock Drops After FDA CRL For Pimavanserin Application In Hallucinations and Dementia-Related Psychosis
- The FDA has issued a Complete Response Letter (CRL) to Acadia Pharmaceuticals Inc (NASDAQ: ACAD) regarding its supplemental marketing application (for Nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP). In the CRL, Psychiatry's division cited a lack of statistical significance in some subgroups of dementia and insufficient numbers of patients with specific less common dementia subtypes.
- 04/05/2021
|
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for NUPLAZID® (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP). The FDA issued a CRL to indicate that they have completed their review of the application and has determined that th
- 04/05/2021
|
These 2 Scrappy Biotechs Could Skyrocket in April
- They've both taken a beating, but their fortunes may soon change.
- 04/04/2021
|
Moving Average Crossover Alert: ACADIA Pharma
- ACADIA Pharmaceuticals (ACAD) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
- 03/24/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys
- San Francisco, California--(Newsfile Corp. - March 15, 2021) - Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims. Visit: www.hbsslaw.com/investor-fraud/ACAD Contact An Attorney Now: ACAD@hbsslaw.com 844-916-0895Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Investigation: The investigation focuses on the accuracy of Acadia's disclosures concerning its supplemental...
- 03/15/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
- New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("ACADIA" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether ACADIA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 03/14/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
- NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("ACADIA" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Robert S.
- 03/12/2021
|
DraftKings, H&R Block, Novartis and More Wednesday Afternoon Analyst Calls
- With the trading day more than halfway over, the broad markets were pushing higher yet again.
- 03/10/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys
- SAN FRANCISCO, March 9, 2021 /PRNewswire/ -- Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims.
- 03/09/2021
|
Acadia Pharmaceuticals stock leads premarket losers after FDA finds undisclosed 'deficiencies' in NDA
- Shares of Acadia Pharmaceuticals Inc. plunged 42.1% to pace all premarket decliners Tuesday, in the wake of the company's announcement that the Food and Drug Administration found undisclosed deficiencies in its supplemental New Drug Application (NDA) for pimavanserin, a treatment for hallucinations and delusions associated with dementia-related psychosis. The company said late Monday that the FDA's identification of deficiencies precluded discussion of labeling and post-marketing requirements.
- 03/09/2021
|
ACAD Stock Price Fell Over 40% Pre-Market: Why It Happened
- The stock price of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) fell by over 40% pre-market. This is why it happened.
- 03/09/2021
|
ACADIA Pharmaceuticals, Inc. (ACAD) Presents at Cowen Healthcare Broker Conference Call - (Transcript)
- ACADIA Pharmaceuticals, Inc. (ACAD) Presents at Cowen Healthcare Broker Conference Call - (Transcript)
- 03/01/2021
|
ACADIA (ACAD) Beats on Q4 Earnings, Misses on Revenues
- ACADIA's (ACAD) loss narrows in the fourth quarter of 2020 while it misses estimates for revenues. Nuplazid drives year-over-year revenues.
- 02/25/2021
|
ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q4 2020 Results - Earnings Call Transcript
- ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q4 2020 Results - Earnings Call Transcript
- 02/24/2021
|
Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Lags Revenue Estimates
- Acadia (ACAD) delivered earnings and revenue surprises of 12.50% and -1.52%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 02/24/2021
|
A Preview Of ACADIA Pharmaceuticals's Earnings
- On Wednesday, February 24, ACADIA Pharmaceuticals (NASDAQ:ACAD) will release its latest earnings report. Check out Benzinga's preview to understand the implications.
- 02/23/2021
|
Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for
- Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/17/2021
|
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on February 24, 2021, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call may be accessed by dialing 855-638-4820 for participants in the United States
- 02/10/2021
|
Acadia: Waxing And Waning Into A Big PDUFA
- After a nice close to 2020, Acadia's shares hit a slick spot in 2021.When they are waxing, as they so often do, Acadia's shares are good candidates for selling covered calls.
- 02/02/2021
|
Acadia Pharmaceuticals Announces Commercial Leadership Change
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Michael Yang, Executive Vice President and Chief Commercial Officer, will be leaving the organization effective January 29, 2021 to assume the role of chief executive officer at another healthcare company. Charmaine Lykins, Senior Vice President, Global Product Planning and Chief Marketing Officer and Amanda Morgan, Senior Vice President, Chief Revenue and Customer Officer, will lead the commercial organ
- 01/27/2021
|
ACADIA Pharmaceuticals Inc.'s (ACAD) CEO Stephen Davis at 39th Annual J.P. Morgan Healthcare Conference (Transcript)
- ACADIA Pharmaceuticals Inc.'s (ACAD) CEO Stephen Davis at 39th Annual J.P. Morgan Healthcare Conference (Transcript)
- 01/12/2021
|
5 Top Biotech Stocks to Buy for 2021 With Massive Upside Potential
- After an incredibly wild and wooly year for investors, many across Wall Street are cautiously optimistic for 2021.
- 12/21/2020
|
Raymond James Top Health Care Picks Crushing S&P 500: 4 Stocks to Buy Now
- The health care sector as a whole has been a top performer this year, and there is every reason to believe that strong performance will carry through to 2021.
- 12/03/2020
|
ACADIA Pharmaceuticals Inc.'s (ACAD) Management Presents at 2020 Stifel Virtual Healthcare Conference (Transcript)
- ACADIA Pharmaceuticals Inc.'s (ACAD) Management Presents at 2020 Stifel Virtual Healthcare Conference (Transcript)
- 11/17/2020
|
What's Behind Acadia Pharmaceuticals' Mixed Q3 Results
- The good news? Sales of Nuplazid are soaring.
- 11/05/2020
|
ACADIA Pharmaceuticals Inc.'s (ACAD) CEO Steve Davis on Q3 2020 Results - Earnings Call Transcript
- ACADIA Pharmaceuticals Inc.'s (ACAD) CEO Steve Davis on Q3 2020 Results - Earnings Call Transcript
- 11/04/2020
|
Why Acadia Healthcare Stock Is Soaring Today
- The company's latest quarterly update impressed investors.
- 10/30/2020
|
Were Hedge Funds Wrong About Embracing ACADIA Pharmaceuticals Inc. (ACAD)?
- Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren't timid and registered double digit market beating gains. Financials, energy and industrial stocks aren't doing great but many of the stocks that delivered strong returns since March are still going very strong and hedge funds actually increased their positions in these stocks. In this article we will find out how hedge fund sentiment to ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) changed recently.
- 10/26/2020
|
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference
- SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that scientific presentations highlighting new analyses of pimavanserin clinical study data in dementia-related psychosis and neurodegenerative diseases will be shared at the 13th Clinical Trials on Alzheimer's Disease Conference (CTAD), being held virtually November 4-7, 2020. Scientific presentations include those investigating pimavanserin treatment and its impact on cognition and motor function in patient
- 10/26/2020
|
ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis Presents at Morgan Stanley 18th Annual Global Healthcare Conference (Transcript)
- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Morgan Stanley 18th Annual Global Healthcare Conference September 14, 2020 03:45 PM ET Company Participants Steve Davis - CEO Serge Stankovic - President Elena Ridloff - CFO Conference Call Participants Jeff Hung - Morgan Stanley Presentation Jeff Hung Welcome to the Morgan Stanley Global Healthcare Conference.
- 09/14/2020
|
ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020
- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at The JMP Securities CNS Forum on Wednesday, August 19, 2020, at 11:00 a.m. Eastern Time.
- 08/12/2020
|
Needham & Company LLC Reaffirms “Buy” Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)
- ACADIA Pharmaceuticals (NASDAQ:ACAD)‘s stock had its “buy” rating reissued by Needham & Company LLC in a report released on Thursday, TipRanks reports. They currently have a $60.00 price target on the biopharmaceutical company’s stock. Needham & Company LLC’s price objective indicates a potential upside of 37.52% from the company’s current price. Several other analysts have […]
- 08/09/2020
|
ACADIA (ACAD) Q2 Earnings Surpass, Nuplazid Drives Sales
- ACADIA (ACAD) beats on earnings and revenues for the second quarter. The company lifts the lower end of its net sales view for Nuplazid, driving the stock in pre-market trading.
- 08/06/2020
|
Analysts Offer Insights on Healthcare Companies: Aileron Therapeutics (NASDAQ: ALRN), ACADIA Pharmaceuticals (NASDAQ: ACAD) and Globus Medical (NYSE: GMED) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aileron Therapeutics
- 08/06/2020
|
Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates
- Acadia (ACAD) delivered earnings and revenue surprises of 38.64% and 4.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/05/2020
|
ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results
- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the second quarter ended June 30, 2020.
- 08/05/2020
|
The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
ABIOMED, Inc. (NASDAQ: ABMD) (FDA approved the emergency use of Abiomed's Impella heart pump in combination...
- 08/05/2020
|
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
- Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
- 08/02/2020
|
SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of ACADIA Pharmaceuticals Inc. (ACAD)
- San Diego, California--(Newsfile Corp. - July 31, 2020) - If you would like to discuss your legal rights email leo@barrlaw.com or call (619) 780-3993. ACADIA Pharmaceuticals (ACAD) Accused of Misleading Shareholders. Securities Class Action Survives Motion to Dismiss In Part, Paving the Way for Litigation to Proceed.Purchasers of Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) have filed a class action complaint ...
- 08/01/2020
|
SHAREHOLDER ALERT: Stephens & Stephens LLP Investigating the Officers and Directors of ACADIA Pharmaceuticals Inc. (ACAD)
- Stephens & Stephens LLP is investigating the officers and directors of ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD) for breach of fiduciary duties on the part of its directors and management.
- 07/30/2020
|
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/29/2020
|
People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey Highlights
- UsAgainstAlzheimer’s, the Lewy Body Dementia Association and ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the results of a qualitative and quantitative survey that explored the impact of dementia-related psychosis on more than 200 patients to better understand the patient-centered experience of symptoms and unmet treatment needs. Both patients and caregivers responded to the survey. These data were presented today in two posters during the Alzheimer's Association International Conference® (AAIC) virtual event, convening July 27-31, 2020.
- 07/29/2020
|
ACADIA Pharmaceuticals (ACAD) Investor Presentation - Slideshow
- The following slide deck was published by ACADIA Pharmaceuticals Inc. in conjunction with this event..
- 07/29/2020
|
ACADIA (ACAD) to Report Q2 Earnings: What's in the Cards?
- ACADIA's (ACAD) second-quarter 2020 results are likely to reflect lower revenues from Nuplazid due to the adverse impacts of COVID-19.
- 07/28/2020
|
Analysts' Top Healthcare Picks: Protalix Biotherapeutics (PLX), ACADIA Pharmaceuticals (ACAD) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Protalix Biotherapeutics
- 07/27/2020
|
Brokerages Expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Will Announce Earnings of -$0.45 Per Share
- Brokerages expect that ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) will post earnings per share (EPS) of ($0.45) for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for ACADIA Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.50) and the highest is ($0.37). ACADIA Pharmaceuticals reported earnings per share of ($0.38) in the same […]
- 07/27/2020
|
ACADIA Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020
- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 5, 2020, after the close of the U.S. financial markets. ACADIA’s management team will also host a conference call and webcast on Wednesday, August 5, 2020, at 4:30 p.m. Eastern Time to discuss financial results and operations.
- 07/22/2020
|
Stocks Little Changed As Risk-On Trade Comes Into Focus
- Stocks Analysis by Michael Kramer covering: SPDR S&P 500, Amazon.com Inc, Freeport-McMoran Copper & Gold Inc, US Dollar Index Futures. Read Michael Kramer's latest article on Investing.com
- 07/22/2020
|
Acadia Pharma Dives On Unexpected Flop In Depression Treatment
- Acadia Pharmaceuticals said Tuesday its experimental depression treatment failed in a Phase 3 study — prompting ACAD stock to plunge. That put shares near their lowest point this month.
- 07/21/2020
|
Charting a bull-flag breakout, S&P 500 extends rally as volatility recedes
- Technically speaking, the U.S. benchmarks’ bigger-picture backdrop remains bullish, and continues to strengthen, amid recently receding volatility, writes...
- 07/21/2020
|
Acadia Plunges 12% As Depressive Study Misses Goals; Analyst Says Buy
- Shares in Acadia Pharmaceuticals (ACAD) plunged 12% in Monday’s extended trading, after the company announced disappointing top-line results from its 298 patient Phase 3 CLARITY study evaluating pimavanserin as an adjunctive treatment for major depressive disorder (MDD).The study did not achieve statistical significance on the primary endpoint which was the 17-item Hamilton Depression Rating Scale (HAMD-17) total score change from baseline to week 5. Pimavanserin 34 mg, given once-daily as an adjunctive treatment to standard antidepressant therapy was associated with a mean reduction of 9.0 in HAMD-17 total score compared to 8.1 for placebo as an adjunctive treatment (p=0.296).Positive results were observed on the key secondary endpoint, the Clinical Global Impression – Severity (CGI-S) score, a clinician assessment of a patient’s severity of depression (nominal p=0.042) and on the Karolinska Sleepiness Scale (KSS) score (nominal p=0.005).“We observed a consistent improvement of depressive symptoms over time with pimavanserin but, unfortunately, the robust positive results from our CLARITY-1 study were not replicated,” said Serge Stankovic, ACADIA’s President. “While these results do not support the product profile to pursue an additional Phase 3 study in adjunctive MDD, we will continue to analyze the data and the findings from our earlier positive depression studies as we assess next steps.”In the study, pimavanserin was generally well-tolerated when added to existing antidepressant therapy, and similar rates of adverse events were observed between pimavanserin (58.1%) and placebo (54.7%).However, on a more positive note, the company also announced that the FDA accepted Nuplazid’s (pimavanserin) supplemental new drug application (sNDA) for dementia-related psychosis (DRP). The PDUFA date for the FDA’s decision is set for April 3, 2021.“Nuplazid’s Phase 3 failure in major depressive disorder (MDD) is certainly disappointing but not entirely surprising given how difficult a nut this indication is to crack” commented JP Morgan analyst Cory Kasimov following the update.However he remains bullish on ACAD’s longer-term outlook and the DRP indication specifically. “We remain highly confident in the approvability of DRP” the analyst commented. He has a buy rating on the stock and $66 price target (19% upside potential).Shares in ACAD are up 30% year-to-date, and the stock shows a bullish Strong Buy analyst consensus. That’s with an average analyst price target of $60 (8% upside potential). (See ACAD stock analysis on TipRanks)Related News: Pfizer, BioNTech Ink UK Supply Deal For 30M Covid-19 Vaccine Doses NuVasive Spikes 5% After-Hours On Sharp Procedure Rebound GSK Buys 10% Stake In Germany’s CureVac To Develop mRNA Vaccines More recent articles from Smarter Analyst: * IBM Pops 5% in Extended Trading After Quarterly Profit Beats Expectations * NuVasive Spikes 5% After-Hours On Sharp Procedure Rebound * Apple iPhone SE Boosts Q2, But Unlikely To Cannibalize 5G Sales – Report * Is Nokia Stock a Buy Right Now? This Is What You Need to Know
- 07/21/2020
|
Mid-Afternoon Market Update: Silver Jumps Over 7%; Immuron Shares Spike Higher
- Toward the end of trading Tuesday, the Dow traded up 1.01% to 26949.66 while the NASDAQ fell 0.04% to 10,770.41. The S&P also rose, gaining 0.66% to 3,273.14.
The U.S. has the...
- 07/21/2020
|
U.S. FDA accepts Acadia's application for dementia drug
- The U.S. Food and Drug Administration on Monday accepted Acadia Pharmaceuticals Inc's application for an antipsychotic drug to treat dementia patients with hallucinations and delusions. The drug, Nuplazid, was approved in the United States in 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. In June, Acadia submitted a supplemental new drug application (sNDA) for Nuplazid for the treatment of hallucinations and delusions associated with dementia-related psychosis, which affects about 30% of all patients with dementia in the United States, the company said.
- 07/20/2020
|
ACADIA Pharmaceuticals Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its supplemental New Drug Application (sNDA) for NUPLAZID® (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP).
- 07/20/2020
|
ACADIA Pharmaceuticals Announces Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from its 298 patient Phase 3 CLARITY study which combined two identical, double-blind, placebo-controlled studies evaluating the efficacy, safety and tolerability of pimavanserin as an adjunctive treatment for major depressive disorder (MDD). The combined efficacy and safety analysis was pre-specified prior to data unblinding following feedback from the FDA.
- 07/20/2020
|
ACADIA Pharmaceuticals (ACAD) Receives a Buy from Needham - Markets
- In a report released today, Alan Carr from Needham assigned a Buy rating to ACADIA Pharmaceuticals (ACAD – Research Report),
- 07/16/2020
|
Charting a bull-trend whipsaw, S&P 500 nails next resistance
- Technically speaking, the U.S. benchmarks have registered a mid-July market whipsaw, writes Michael Ashbaugh, pressured at least briefly amid the month’s...
- 07/14/2020
|
Did Hedge Funds Make The Right Call On ACADIA Pharmaceuticals Inc. (ACAD) ?
- The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]
- 07/13/2020
|
Treatment-resistant depression (TRD) Market Trends & Epidemiology Forecasts to 2030 - Cariprazine (Allergan/Gedeon Richter) Expected to be Launched in the US Market by 2022 - ResearchAndMarkets.com
|
Exane Derivatives Sells 727 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
- Exane Derivatives lowered its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 15.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,991 shares of the biopharmaceutical company’s stock after selling 727 shares during the period. Exane Derivatives’ holdings in ACADIA […]
- 07/12/2020
|
Shareholders Are Thrilled That The ACADIA Pharmaceuticals (NASDAQ:ACAD) Share Price Increased 113%
- The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a...
- 07/08/2020
|
The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 7)
AbbVie Inc (NYSE: ABBV)...
- 07/08/2020
|
Why Acadia Pharmaceuticals (ACAD) Stock is a Compelling Investment Case
- If you are looking for the best ideas for your portfolio you may want to consider some of Mott Capital's top stock picks. Mott Capital, an investment management firm, is bullish on Acadia Pharmaceuticals Inc (NASDAQ:ACAD) stock. In its Q4 2019 investor letter – you can download a copy here – the firm discussed its […]
- 07/07/2020
|
Acadia Pharmaceuticals: Evaluating The Upcoming Opportunities (NASDAQ:ACAD)
- With the three sNDA approvals in the next three years, the share price is set to soar. Long-term investors could be generously rewarded with returns.
- 07/07/2020
|
The Daily Biotech Pulse: Novavax Lands $1.6B For COVID-19 Vaccine, Amgen Prevails In Avastin Biosimilar Lawsuit, Cellectis Study Placed On Clinical Hold
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 6)
ACADIA Pharmaceuticals Inc...
- 07/07/2020
|
89bio (ETNB) Receives a Buy from Oppenheimer - Markets
- Oppenheimer analyst Jay Olson maintained a Buy rating on 89bio (ETNB – Research Report) today and set a price target
- 07/02/2020
|
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Bought by Royal Bank of Canada
- Royal Bank of Canada increased its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 40.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 194,543 shares of the biopharmaceutical company’s stock after purchasing an additional 56,079 shares during the period. Royal Bank […]
- 07/01/2020
|
Analysts Offer Insights on Healthcare Companies: Catasys (NASDAQ: CATS), Akero Therapeutics (NASDAQ: AKRO) and Zynerba Pharmaceuticals (NASDAQ: ZYNE) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Catasys (CATS
- 07/01/2020
|
Oppenheimer Reaffirms Their Buy Rating on Marinus (MRNS) - Markets
- Oppenheimer analyst Jay Olson maintained a Buy rating on Marinus (MRNS – Research Report) yesterday and set a price target
- 07/01/2020
|
RBC Capital Remains a Hold on Iterum Therapeutics (ITRM) - Markets
- RBC Capital analyst Gregory Renza maintained a Hold rating on Iterum Therapeutics (ITRM – Research Report) yesterday and set a
- 06/30/2020
|
Needham Thinks Intercept Pharma's Stock is Going to Recover - Markets
- In a report released today, Alan Carr from Needham assigned a Buy rating to Intercept Pharma (ICPT – Research Report),
- 06/30/2020
|
Analysts Offer Insights on Healthcare Companies: Cryolife (NYSE: CRY) and Seattle Genetics (NASDAQ: SGEN) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cryolife (CRY
- 06/30/2020
|
Dow Surges 2.3% as Boeing Begins Testing the 737 Max
- Stocks Analysis by Zacks Investment Research covering: Boeing Co, Ciena Corp, Lennar Corporation, Verizon Communications Inc. Read Zacks Investment Research's latest article on Investing.com
- 06/30/2020
|
Biotech Could Burst Higher, Says Signal
- ACADIA stock is flashing a bull signal that could launch it back toward its all-time highs
- 06/29/2020
|
Analyst Explains Why They Downgraded Their Rating on Intercept Pharma (ICPT) - Markets
- In a report released today, Jay Olson from Oppenheimer downgraded Intercept Pharma (ICPT – Research Report) to Hold, with a
- 06/29/2020
|
Biotech Could Burst Higher, Says Signal - Schaeffer's Investment Research
- Several layers of support are in place for ACADIA Pharmaceuticals Inc (ACAD)
- 06/29/2020
|
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Acquired by Legal & General Group Plc
- Legal & General Group Plc grew its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 8.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 78,098 shares of the biopharmaceutical company’s stock after purchasing an additional 5,820 shares during the period. Legal & General Group Plc’s holdings […]
- 06/26/2020
|
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
- The following is a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 24)
ACADIA...
- 06/25/2020
|
Needham Believes Rhythm Pharmaceuticals (NASDAQ: RYTM) Still Has Room to Grow - Markets
- Needham analyst Alan Carr assigned a Buy rating to Rhythm Pharmaceuticals (RYTM – Research Report) today and set a price
- 06/24/2020
|
2 Biotech Stocks With Major Incoming Catalysts | The Motley Fool
- While everyone's focused on COVID-19, these drugmakers are looking forward to unrelated FDA approvals that could push their stock prices into the clouds.
- 06/24/2020
|
The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 23)
ACADIA Pharmaceuticals Inc...
- 06/24/2020
|
ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis Hosts 2020 Annual Meeting of Stockholders (Transcript)
- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) 2020 Annual Meeting of Stockholders June 23, 2020 10:00 AM ET Company Participants Steve Biggar - Chairman of the Boar
- 06/23/2020
|
Ayala Pharmaceuticals (AYLA) Receives a Buy from Oppenheimer - Markets
- In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on Ayala Pharmaceuticals (AYLA – Research Report),
- 06/23/2020
|
Xconomy: Engrail Therapeutics Launches With $32M to Develop New Neuro Drugs
- Typically a new biotech assembles a group of investors that collectively puts in the money a fledgling company requires to develop or acquire potential
- 06/18/2020
|
US Bancorp DE Purchases 1,818 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
- US Bancorp DE grew its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 48.9% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,538 shares of the biopharmaceutical company’s stock after acquiring an additional 1,818 shares during the quarter. US Bancorp DE’s holdings in […]
- 06/18/2020
|
3 “Strong Buy” Healthcare Stocks That Should Remain Healthy
- For those that thought the extreme market volatility was behind us, think again. Last week, another burst of volatility was brought on by concerns about the U.S. economic recovery and a second wave of COVID-19. This week, however, U.S. stocks recovered some lost ground thanks to strong retail sales data. There's a lot going on in the markets, and the only certainty is uncertainty.Against this backdrop, we turned our attention to defensive stocks in the healthcare sector. In general, these stocks provide stable earnings regardless of the stock market’s state due to the constant demand for their products or services.With this in mind, we used TipRanks’ database to identify three defensive healthcare stocks with upside potential north of 20%. Not to mention each of these companies has earned a “Strong Buy” consensus rating from the analyst community.Deciphera Pharmaceuticals (DCPH)We will start with Deciphera, a biopharmaceutical company which develops cancer medications. On May 15, the company received FDA approval for its QINLOCK™ therapy. The drug is used for the treatment of fourth-line gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract.The good news didn’t end there. On June 8, Deciphera announced that The Lancet Oncology (a medical journal) published positive results from the INVICTUS Phase 3 study of QINLOCK, which featured patients who have been previously treated with anticancer therapies. Data from the study showed a statistically significant improvement in the progression free survival in patients randomized to QINLOCK, compared with patients receiving a placebo.5-star analyst Christopher Raymond, of Piper Sandler, expressed enthusiasm for QINLOCK. Soon after the company received the FDA’s stamp of approval, the analyst said he expects “meaningful upside in coming months as the setup for the launch of QINLOCK remains quite positive.”As a result, Raymond rates DCPH an Outperform (i.e. Buy). The analyst believes the stock has more room to run, as he maintains a $75 price target. This implies upside potential of 21% from current levels. (To watch Raymond’s track record, click here)Like Raymond, other analysts are also bullish on the stock. The 11 ratings on the stock include 9 Buys, only 2 Holds and no Sells, adding up to a Strong Buy consensus rating. The average price target of $71.20 represents a possible 15% increase from the share price of $59.50. (See Deciphera stock analysis on TipRanks)Laboratory Corporation of America (LH)Up next is Laboratory Corporation of America, which operates two divisions, LabCorp Diagnostics (LCD) and Covance Drug Development. LCD provides clinical laboratory services such as blood, urine, and COVID-19 tests, while Covance offers services that help clients manage the drug development process.The company’s sales were only slightly affected by the COVID-19 pandemic. Revenue for the first quarter of 2020 was $2.8 billion, an increase of 1.2% from the prior-year quarter. The increase in revenue was due to acquisitions, partially offset by the negative impact from COVID-19. However, earnings took a bigger hit thanks to the public health crisis, as the operating loss for the quarter was $193 million, compared to operating income of $318 million in the first quarter of 2019.J.P. Morgan analyst Lisa Gill believes Laboratory is better positioned than the competition because of its income diversity, with it also less exposed to upcoming Medicare cuts. To provide additional support for her bullish thesis, the 5-star analyst cites improving trends in the company’s core business.To this end, Gill rates LH an Overweight (i.e. Buy), while raising her price target from $118 to $223. The new figure implies upside potential of 31% from current levels. (To watch Gill’s track record, click here)Turning now to the rest of the Street, most other analysts are on the same page. Laboratory has a Strong Buy analyst consensus rating comprised of 10 Buys, 3 Holds and no Sell ratings. The average price target on the stock is $213.27, which suggests 25% upside potential. (See LH stock analysis on TipRanks)ACADIA Pharmaceuticals (ACAD)Last on our list is ACADIA, a biopharmaceutical company that designs medications for central nervous system disorders. ACADIA has developed the only approved therapy for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, NUPLAZID.Despite COVID-19, sales of NUPLAZID increased 43% to reach $90.1 million for the three months ended March 31, 2020, compared to $63 million in the first quarter of 2019. In addition, management announced it completed a pre-sNDA meeting (a meeting between a company and the FDA to ensure the submission of a well-organized NDA), and is on-track to submit a supplemental NDA this summer for NUPLAZID as a potential breakthrough therapy for DRP (drug related problems) and MDD (major depressive disorder).5-star analyst Charles Duncan, representing Cantor Fitzgerald, viewed management’s announcement positively. In a recent research note, he cited the company’s positive outlook as a major component of his bullish thesis. “Pipeline driven potential is more than additive to our view that NUPLAZID is continuing to gain traction on volume growth by increasing penetration and persistence,” he stated.To this end, Duncan has an Overweight (i.e. Buy) rating on the stock. Along with his rating, the analyst gave the price target a lift, from $58 to $63, implying 34% upside potential. (To watch Duncan’s track record, click here).Other analysts on the Street agree with Duncan and also have high expectations for the stock, with 9 Buys and 1 Hold resulting in a Strong Buy consensus rating. The average price target is $60.30, which implies upside potential of 27%. (See ACADIA stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 06/17/2020
|
Oppenheimer Assigns a Buy Rating on Neurocrine (NBIX) - Markets
- In a report released today, Jay Olson from Oppenheimer assigned a Buy rating to Neurocrine (NBIX – Research Report), with
- 06/16/2020
|
Analysts' Top Healthcare Picks: Albireo Pharma (ALBO), Monopar Therapeutics Inc (MNPR) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Albireo Pharma
- 06/16/2020
|
Neurocrine (NBIX) Gets a Hold Rating from Needham - Markets
- Needham analyst Alan Carr assigned a Hold rating to Neurocrine (NBIX – Research Report) today. The company’s shares closed last
- 06/16/2020
|
ACADIA Files sNDA for Nuplazid in Dementia-Related Psychosis
- ACADIA (ACAD) files an sNDA for Nuplazid's potential second indication to treat hallucinations and delusions linked to dementia-related psychosis.
- 06/16/2020
|
Acadia Files Nuplazid Label Expansion; Analyst Sees 'Significant' Potential
- Acadia Pharmaceuticals Inc. (ACAD) has announced that it has filed a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration
- 06/16/2020
|
Oppenheimer Issues a Buy Rating on Incyte (INCY) - Markets
- In a report released today, Jay Olson from Oppenheimer assigned a Buy rating to Incyte (INCY – Research Report), with
- 06/15/2020
|
ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the company submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to support a potential new indication for NUPLAZID® (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP). The FDA previously granted Breakthrough Therapy Designation for pimavanserin for the treatment of hallucinations and delusions associated with DRP.
- 06/15/2020
|
Crispr Therapeutics AG (CRSP) Gets a Buy Rating from Needham - Markets
- In a report released today, Alan Carr from Needham assigned a Buy rating to Crispr Therapeutics AG (CRSP – Research
- 06/12/2020
|
Hedge Funds Are Selling ACADIA Pharmaceuticals Inc. (ACAD)
- At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]
- 06/08/2020
|
Why Is Acadia (ACAD) Down 7.6% Since Last Earnings Report?
- Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- 06/06/2020
|
Hedge Funds Are Selling ACADIA Pharmaceuticals Inc. (ACAD)
- At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]
- 06/06/2020
|
ACADIA Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020
- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020, at 4:40 p.m. Eastern Time.
- 06/02/2020
|
Is Acadia Pharmaceuticals a Buy?
- A strong Q1 performance set the tone, but commitment to its strategy will be key to drive the stock higher.
- 06/02/2020
|
ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer
|
ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer
- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today announced that Mark Schneyer has been appointed to the newly created position of Senior Vice President, Business Development and Chief Business Officer. Mr. Schneyer will be responsible for sourcing and executing business development opportunities and serve as a member of the company’s Executive Management Committee. He will report to Steve Davis, Chief Executive Officer.
- 05/28/2020
|
ACADIA to Merge Two Phase III Studies on Nuplazid for MDD
- ACADIA (ACAD) to club two late-stage studies on Nuplazid into a single evaluation program for the adjunctive treatment of MDD. Top-line results from the same are expected in Q3.
- 05/27/2020
|
Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $53
|
Stocks Will Try To Rise On May 27 On More Stimulus Hopes
|
ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
|
ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that following positive feedback from the U.S. Food and Drug Administration the company plans to combine its CLARITY-2 and CLARITY-3 Phase 3 studies evaluating pimavanserin for the adjunctive treatment of major depressive disorder (MDD) into one study with a pre-specified statistical analysis plan. As a result, no new patients will be enrolled in the two identically designed Phase 3 studies, each of which will be concluded with slightly more than 50% enrollment. Top-line results from the combined study are expected in the third quarter of 2020.
- 05/26/2020
|
Insights into the US Digital Therapeutics Industry to 2025 - Featuring Noom, Livongo Health & Omada Health Among Others - ResearchAndMarkets.com
|
Edited Transcript of ACAD earnings conference call or presentation 7-May-20 8:30pm GMT
- Q1 2020 ACADIA Pharmaceuticals Inc Earnings Call
- 05/22/2020
|
ACADIA Pharma Will Present Pimavanserin Data At American Society Of Clinical Psychopharmacology Meeting May 29-30
|
ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 American Society of Clinical Psychopharmacology Virtual Annual Meeting
- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that multiple scientific presentations and abstracts evaluating pimavanserin in clinical studies for the treatment of various central nervous system (CNS) disorders will be highlighted at the 2020 American Society of Clinical Psychopharmacology (ASCP) Virtual Annual Meeting on May 29-30, 2020.
- 05/21/2020
|
Acadia Pharmaceuticals Inc (ACAD) CEO Stephen Davis Sold $9.— million of Shares
|
Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C. and Los Angeles County.
|
Sectoral Asset Management Inc Buys Exelixis Inc, Seattle Genetics Inc, Deciphera ...
|
Birchview Capital, LP Buys ACADIA Pharmaceuticals Inc, Biogen Inc, Neurocrine Biosciences Inc, ...
|
Analysts Have Made A Financial Statement On ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) First-Quarter Report
- It's been a pretty great week for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shareholders, with its shares surging 13...
- 05/09/2020
|
Acadia Pharmaceuticals (ACAD) Q1 2020 Earnings Call Transcript
- ACAD earnings call for the period ending March 31, 2020.
- 05/09/2020
|
Edited Transcript of ACAD earnings conference call or presentation 7-May-20 8:30pm GMT
- Q1 2020 ACADIA Pharmaceuticals Inc Earnings Call
- 05/08/2020
|
JP Morgan Maintains Overweight on ACADIA Pharmaceuticals, Raises Price Target to $55
|
ACADIA's (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates
- ACADIA's (ACAD) earnings and sales lag estimates in the first quarter of 2020. The company trims its 2020 revenue guidance due to the coronavirus impact. Stock declines in after-hours trading.
- 05/08/2020
|
ACADIA Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 EPS and sales results.UPDATE: Shares have since reversed, now higher.
|
38 Stocks Moving in Friday's Pre-Market Session
|
Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Raises Price Target to $63
|
ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q1 2020 Results - Earnings Call Transcript
- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2020 Earnings Conference Call May 7, 2020 4:30 PM ET Company Participants Mark Johnson - Vice President of Investor
- 05/08/2020
|
ACADIA's (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates
|
Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates
- Acadia (ACAD) delivered earnings and revenue surprises of -23.91% and -3.36%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/07/2020
|
ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results
- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the quarter ended March 31, 2020.
- 05/07/2020
|
ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration
- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Vanderbilt University today announced an exclusive worldwide license agreement to develop and commercialize novel drug candidates targeting the muscarinic M1 receptor with the potential to treat a range of central nervous system (CNS) disorders. The collaboration will focus on positive allosteric modulators (PAMs) of the M1 receptor.
- 05/07/2020
|
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
- 05/07/2020
|
ACADIA Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences
- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the following two investor conferences:
- 05/05/2020
|
Start-up gets $1 billion valuation virtually, as coronavirus shifts Silicon Valley hunt for IPO riches
- When VAST Data became a unicorn, valued at over $1 billion, in April, it relied on virtual meetings with investors, as Silicon Valley VCs and the IPO market navigate Covid-19.
- 05/05/2020
|
5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates
|
Acadia Pharmaceuticals: Targeting A Strong Return By Year End
- After a huge rally in April, stocks finally saw some significant profit taking last week, leaving some good stocks with lower entry levels. This includes Acadia
- 05/04/2020
|
3 Promising Biotech Stocks to Buy on a Market Pullback
- Eagle Pharmaceuticals, Biohaven Pharmaceuticals and Acadia Pharmaceuticals are names to consider on a 10% move down in equities.
- 05/04/2020
|
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
- Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
- 05/03/2020
|
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Down 7% Following Insider Selling
- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s stock price traded down 7% on Friday following insider selling activity. The stock traded as low as $44.22 and last traded at $44.93, 1,186,651 shares changed hands during trading. A decline of 15% from the average session volume of 1,402,762 shares. The stock had previously closed at $48.31. Specifically, President Srdjan […]
- 05/02/2020
|
Viking Therapeutics (VKTX) Received its Third Buy in a Row
- After William Blair and Stifel Nicolaus gave Viking Therapeutics (NASDAQ: VKTX) a Buy rating last month, the company received another Buy, this time from
- 05/01/2020
|
Viking Therapeutics (VKTX) Received its Third Buy in a Row
- After William Blair and Stifel Nicolaus gave Viking Therapeutics (NASDAQ: VKTX) a Buy rating last month, the company received another
- 05/01/2020
|
ACADIA Pharmaceuticals (NASDAQ:ACAD) Downgraded by BidaskClub to Hold
- ACADIA Pharmaceuticals (NASDAQ:ACAD) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday, BidAskClub reports. Several other research analysts have also issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $75.00 price target (up […]
- 05/01/2020
|
Oppenheimer Believes Amgen (AMGN) Won't Stop Here
- Oppenheimer analyst Jay Olson assigned a Buy rating to Amgen (AMGN) today and set a price target of $252.00. The company's shares closed last Thursday at
- 05/01/2020
|
Oppenheimer Believes Amgen (NASDAQ: AMGN) Won’t Stop Here
- Oppenheimer analyst Jay Olson assigned a Buy rating to Amgen (AMGN – Research Report) today and set a price target
- 05/01/2020
|
Acadia Pharmaceuticals Inc (ACAD) EVP and CFO Elena Ridloff Sold $559,…—… of Shares
|
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
- Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/30/2020
|
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
- Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/30/2020
|
Russell 2000 Retreats
- The Russell 2000 Index is pulling back today after hitting a major resistance level yesterday.
- 04/30/2020
|
Wall Street Analysts Are Neutral on Top Healthcare Picks
- Analysts fell to the sidelines weighing in on Vertex Pharmaceuticals (VRTX), United Therapeutics (UTHR) and Alkermes (ALKS) with neutral ratings,
- 04/30/2020
|
Columbus Circle Investors Has $7.35 Million Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
- Columbus Circle Investors boosted its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 162.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 174,038 shares of the biopharmaceutical company’s stock after buying an additional 107,829 shares during the quarter. Columbus Circle Investors owned approximately 0.11% […]
- 04/30/2020
|
ACADIA Pharmaceuticals (ACAD) Set to Announce Quarterly Earnings on Thursday
- ACADIA Pharmaceuticals (NASDAQ:ACAD) will be releasing its earnings data after the market closes on Thursday, May 7th. Analysts expect ACADIA Pharmaceuticals to post earnings of ($0.45) per share for the quarter. ACADIA Pharmaceuticals has set its FY 2020 After-Hours guidance at EPS.Persons that are interested in registering for the company’s earnings conference call can do […]
- 04/30/2020
|
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
|
Analysts Offer Insights on Healthcare Companies: LivaNova (LIVN), Crispr Therapeutics AG (CRSP) and Encompass Health (EHC)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on LivaNova (LIVN), Crispr Therapeutics AG (CRSP) and
- 04/29/2020
|
Analysts Offer Insights on Healthcare Companies: LivaNova (NASDAQ: LIVN), Crispr Therapeutics AG (NASDAQ: CRSP) and Encompass Health (NYSE: EHC)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on LivaNova (LIVN
- 04/29/2020
|
Gilead Sciences (GILD) Gets a Hold Rating from Needham
- In a report released today, Alan Carr from Needham assigned a Hold rating to Gilead Sciences (GILD). The company's shares closed last Wednesday at $83.05,
- 04/29/2020
|
Gilead Sciences (GILD) Gets a Hold Rating from Needham
- In a report released today, Alan Carr from Needham assigned a Hold rating to Gilead Sciences (GILD – Research Report).
- 04/29/2020
|
The Michael J. Fox Foundation Releases New Video Resource to Empower Patients and Families to Participate in Critical Parkinson's Research
- The Michael J. Fox Foundation for Parkinson's Research (MJFF) has released a new video, "Together, We Can Solve the Parkinson's Puzzle," to illustrate the role each individual within a family and community can play to help scientists piece together a fuller picture of Parkinson'
- 04/29/2020
|
10 Stocks to Buy for an Aging Population
- Aging seniors have been put firmly in the crosshairs of the novel coronavirus. These 10 stocks to buy will benefit from this brutal reality.
- 04/28/2020
|
Oppenheimer Maintains a Buy Rating on Neurocrine (NBIX)
- Oppenheimer analyst Jay Olson maintained a Buy rating on Neurocrine (NBIX) today and set a price target of $130.00. The company's shares closed last
- 04/28/2020
|
Oppenheimer Maintains a Buy Rating on Neurocrine (NBIX)
- Oppenheimer analyst Jay Olson maintained a Buy rating on Neurocrine (NBIX – Research Report) today and set a price target
- 04/28/2020
|
Karuna Therapeutics (KRTX) Gets a Buy Rating from Oppenheimer
- Oppenheimer analyst Jay Olson initiated coverage with a Buy rating on Karuna Therapeutics (KRTX) today and set a price target of $125.00. The company's
- 04/27/2020
|
Karuna Therapeutics (KRTX) Gets a Buy Rating from Oppenheimer
- Oppenheimer analyst
Jay Olson
initiated coverage with a
Buy
rating on Karuna Therapeutics (
KRTX
–
Research Report
) today and set a price target of
$125.00
. The company’s shares closed last Monday at $86.17.
According to
TipRanks.com
, Olson is ran
- 04/27/2020
|
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and CTI BioPharma (CTIC)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neurocrine (NBIX) and CTI BioPharma (CTIC). Neurocrine (NBIX) In a
- 04/27/2020
|
Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and CTI BioPharma (NASDAQ: CTIC)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neurocrine (
NBIX
–
Research Report
) and CTI BioPharma (
CTIC
–
Research Report
).
Neurocrine (NBIX)
In a report released today,
Alan Carr
from Needham assigned a
Hold
- 04/27/2020
|
Needham Gives a Hold Rating to Lexicon Pharmaceuticals (LXRX)
- In a report released today, Alan Carr from Needham assigned a Hold rating to Lexicon Pharmaceuticals (LXRX). The company's shares closed last Monday at
- 04/27/2020
|
Needham Gives a Hold Rating to Lexicon Pharmaceuticals (LXRX)
- In a report released today,
Alan Carr
from Needham assigned a
Hold
rating to Lexicon Pharmaceuticals (
LXRX
–
Research Report
). The company’s shares closed last Monday at $2.26.
According to
TipRanks.com
, Carr is a 1-star analyst with an average re
- 04/27/2020
|
Stocks Are Set To Rise On April 27 But Are Going Nowhere Fast
- The good news is that stocks are pointing to a higher opening on April 27.
- 04/27/2020
|
$93.20 Million in Sales Expected for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) This Quarter
- Equities analysts expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to post sales of $93.20 million for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have made estimates for ACADIA Pharmaceuticals’ earnings. The highest sales estimate is $106.20 million and the lowest is $76.27 million. ACADIA Pharmaceuticals reported sales of $62.96 million during the same […]
- 04/27/2020
|
Fly Insider: Accelerate Diagnostics, Abbott among week's notable insider trades MYOV;AIMT;AXDX;CFG;VOXX;KMB;PGNY;EBS;ABT;ACAD
- Fly Insider: Accelerate Diagnostics, Abbott among week's notable insider trades MYOV AIMT AXDX CFG VOXX KMB PGNY EBS ABT ACAD
- 04/27/2020
|
Oppenheimer Believes Amgen (AMGN) Won't Stop Here
- In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on Amgen (AMGN), with a price target of $250.00. The company's shares
- 04/27/2020
|
Oppenheimer Believes Amgen (NASDAQ: AMGN) Won’t Stop Here
- In a report released yesterday,
Jay Olson
from Oppenheimer maintained a
Buy
rating on Amgen (
AMGN
–
Research Report
), with a price target of
$250.00
. The company’s shares closed last Friday at $236.28, close to its 52-week high of $245.00.
Accordi
- 04/27/2020
|
Stocks Are Set To Rise On April 27 But Are Going Nowhere Fast
|
Many students lack access to internet for remote learning
- BATON ROUGE, La. (AP) — The majority of students in half of Louisiana’s school districts do not have internet at their homes, illuminating a major challenge of shifting to remote learning as schools remain closed due to COVID-19. In a survey for the Louisiana Department of Education, 35 parishes reported that more than 50% of their students do not have home internet access. Thirty-three parishes and city districts reported higher percentages. When Gov. John Bel Edwards announced that students would not return to schools this semester, the department directed all school districts to create and implement a plan for “continuous learning,” also referred to as distance or remote education and learning. Acting State Superintendent of Education Beth Scioneaux encouraged districts to use both high- and “low-tech” methods for instruction, like Google Classroom, Zoom meetings, phone calls and printed paper worksheets. What that needs to look like is different for students depending on where they are located. All students in Monroe City School District have access to internet and a phone they can use for video conferencing, according to survey results. But only 10% of students in rural Vernon Parish can connect to the web at home and 25% with a phone. “We must innovate and work together to overcome these barriers to ensure every child, including those most vulnerable, have access to a quality education,” Scioneaux said in a statement Monday. “School systems need additional support to serve all students. School systems reported needing additional assistance in expanding technology access for students, providing supports and related services to students with disabilities, and providing professional development for teachers to successfully provide continuous...
- 04/26/2020
|
Zacks: Brokerages Anticipate ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to Announce -$0.46 Earnings Per Share
- Analysts expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to post ($0.46) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for ACADIA Pharmaceuticals’ earnings, with estimates ranging from ($0.59) to ($0.36). ACADIA Pharmaceuticals reported earnings per share of ($0.59) during the same quarter last year, which would indicate […]
- 04/25/2020
|
ACADIA HEALTHCARE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Acadia Healthcare Company, Inc. - ACHC
- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Acadia Healthcare Company, Inc. (NasdaqGS: ACHC).
- 04/25/2020
|
Oppenheimer Gives a Hold Rating to Prothena (PRTA)
- In a report released today, Jay Olson from Oppenheimer assigned a Hold rating to Prothena (PRTA). The company's shares closed last Thursday at $11.50.
- 04/23/2020
|
Oppenheimer Gives a Hold Rating to Prothena (PRTA)
- In a report released today,
Jay Olson
from Oppenheimer assigned a
Hold
rating to Prothena (
PRTA
–
Research Report
). The company’s shares closed last Thursday at $11.50.
According to
TipRanks.com
, Olson has currently no stars on a ranking scale of
- 04/23/2020
|
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) President Srdjan R. Stankovic Sells 54,019 Shares
- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) President Srdjan R. Stankovic sold 54,019 shares of the stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $50.02, for a total value of $2,702,030.38. Following the sale, the president now owns 106,027 shares of the company’s stock, valued at $5,303,470.54. The sale […]
- 04/23/2020
|
Srdjan R. Stankovic Sells 100,000 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock
- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) President Srdjan R. Stankovic sold 100,000 shares of the business’s stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $50.15, for a total transaction of $5,015,000.00. Following the completion of the transaction, the president now directly owns 106,027 shares of the company’s stock, […]
- 04/23/2020
|
Biogen (BIIB) Receives a Buy from Oppenheimer
- The company's shares closed last Wednesday at $298.01. According to TipRanks.com, Olson 's ranking currently consits of no stars on a 0-5 ranking scale,
- 04/23/2020
|
Biogen (BIIB) Receives a Buy from Oppenheimer
- The company’s shares closed last Wednesday at $298.01. According to TipRanks.com, Olson ‘s ranking currently consits of no stars on
- 04/23/2020
|
Analysts Offer Insights on Healthcare Companies: Biohaven Pharmaceutical Holding Co (BHVN) and Cara Therapeutics (CARA)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biohaven Pharmaceutical Holding Co (BHVN) and Cara
- 04/22/2020
|
Analysts Offer Insights on Healthcare Companies: Biohaven Pharmaceutical Holding Co (NYSE: BHVN) and Cara Therapeutics (NASDAQ: CARA)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biohaven Pharmaceutical Holding Co (
BHVN
–
Research Report
) and Cara Therapeutics (
CARA
–
Research Report
) with bullish sentiments.
Biohaven Pharmaceut
- 04/22/2020
|
Cara Therapeutics (CARA) Receives a Buy from Needham
- In a report released today, Alan Carr from Needham assigned a Buy rating to Cara Therapeutics (CARA), with a price target of $35.00. The company's shares
- 04/21/2020
|
Cara Therapeutics (CARA) Receives a Buy from Needham
- In a report released today, Alan Carr from Needham assigned a Buy rating to Cara Therapeutics (CARA – Research Report),
- 04/21/2020
|
Needham Gives a Buy Rating to SCYNEXIS (SCYX)
- Needham analyst Alan Carr assigned a Buy rating to SCYNEXIS (SCYX) today and set a price target of $5.00. The company's shares closed last Tuesday at
- 04/21/2020
|
Needham Gives a Buy Rating to SCYNEXIS (SCYX)
- Needham analyst Alan Carr assigned a Buy rating to SCYNEXIS (SCYX – Research Report) today and set a price target
- 04/21/2020
|
2,000 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Purchased by Allred Capital Management LLC
- Allred Capital Management LLC bought a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) during the 1st quarter, HoldingsChannel reports. The institutional investor bought 2,000 shares of the biopharmaceutical company’s stock, valued at approximately $84,000. Several other hedge funds also recently bought and sold shares of the stock. State Street Corp lifted its stake […]
- 04/20/2020
|
Q1 2020 Earnings Forecast for ACADIA Pharmaceuticals Inc. Issued By Jefferies Financial Group (NASDAQ:ACAD)
- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Research analysts at Jefferies Financial Group issued their Q1 2020 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a report issued on Thursday, April 16th. Jefferies Financial Group analyst C. Howerton expects that the biopharmaceutical company will post earnings of ($0.45) per share for the quarter. Jefferies […]
- 04/20/2020
|
The Stock Market Has Gone Insane
- The Fed has made everything right in the world. Earnings don’t matter; valuations do not matter. Why even bother trying to invest any more. Just take all your money and stick it in the SPY and forget it. Maybe it has just become that easy.
- 04/18/2020
|
The Stock Market Has Gone Insane
|
Analysts Conflicted on These Healthcare Names: Alexion Pharmaceuticals (ALXN) and Varian Medical Systems (VAR)
- Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alexion Pharmaceuticals (ALXN) and Varian Medical Systems
- 04/17/2020
|
Needham Maintains a Hold Rating on Gilead Sciences (GILD)
- In a report released today, Alan Carr from Needham maintained a Hold rating on Gilead Sciences (GILD). The company's shares closed last Friday at $82.52,
- 04/17/2020
|
Needham Maintains a Hold Rating on Gilead Sciences (GILD)
- In a report released today,
Alan Carr
from Needham maintained a
Hold
rating on Gilead Sciences (
GILD
–
Research Report
). The company’s shares closed last Friday at $82.52, close to its 52-week high of $85.98.
According to
TipRanks.com
, Carr has 0
- 04/17/2020
|
Exchange Traded Concepts LLC Invests $37,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
- Exchange Traded Concepts LLC bought a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 885 shares of the biopharmaceutical company’s stock, valued at approximately $37,000. Several other hedge funds have […]
- 04/17/2020
|
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG) and Tricida (TCDA)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Intuitive Surgical (ISRG) and Tricida (TCDA). Intuitive Surgical (ISRG)
- 04/17/2020
|
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (NASDAQ: ISRG) and Tricida (NASDAQ: TCDA)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Intuitive Surgical (ISRG – Research
- 04/17/2020
|
Neurodegenerative Disorder Therapeutics Market Global Report (2020 to 2030) - Understand Customers Based on the Latest Market Research Findings
- Dublin, April 17, 2020 -- The "Neurodegenerative Disorder Therapeutics Market Global Report 2020-30" report has been added to ResearchAndMarkets.com's offering..
- 04/17/2020
|
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Vascular Biogenics (VBLT)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB) and Vascular Biogenics (VBLT) with bullish
- 04/17/2020
|
Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and Vascular Biogenics (NASDAQ: VBLT)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB
- 04/17/2020
|
's Top Upgrades, Downgrades For April 16, 2020
- Upgrades
Raymond James upgraded the stock for Ares Capital Corp (NASDAQ: ARCC) from Market Perform to Outperform. For the fourth quarter, Ares Capital had an EPS of...
- 04/16/2020
|
Thursday’s Top Analyst Upgrades and Downgrades: Bed Bath & Beyond, Ciena, DocuSign, eHealth, Faceboook, Netflix, PNC, Square, Tilray, Twitter, Zoom and More
- Stocks closed down on Wednesday as the economic numbers are starting to show just how weak the economy is becoming, but a drop in jobless claims (to 5.25 million) has allowed stocks to rise less than 1% on Thursday morning. Investors have been caught off guard in many of the moves in recent weeks, and […]
- 04/16/2020
|
Jefferies cuts view on Tilray in premarket analyst action
- ACADIA Pharmaceuticals (NASDAQ:ACAD) initiated with a Buy rating and a $60 (33% upside) price target at Jefferies.eHealth (NASDAQ:EHTH) initiated with an Overweight rating and a $150 (26% upside) pric
- 04/16/2020
|
Jefferies Initiates Coverage On ACADIA Pharmaceuticals with Buy Rating, Announces Price Target to $60
|
Madrigal Pharmaceuticals (MDGL) Gets a Buy Rating from Oppenheimer
- Oppenheimer analyst Jay Olson maintained a Buy rating on Madrigal Pharmaceuticals (MDGL) today and set a price target of $200.00. The company's shares
- 04/15/2020
|
Madrigal Pharmaceuticals (MDGL) Gets a Buy Rating from Oppenheimer
- Oppenheimer analyst Jay Olson maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price
- 04/15/2020
|
ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020
- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Thursday, May 7, 2020, after the clo
- 04/15/2020
|
